Browse Locations ... - Conditions: Diabetes; Diabetic Macular Edema; Diabetic Retinopathy
Intervention: Device: OCT imaging
Sponsors: Joslin Diabetes Center; Joslin Diabetes Center; Genentech; Juvenile Diabetes Research Foundation; Optovue
Not yet recruiting - verified June 2013 - Conditions: Dilated Cardiomyopathy; Hypertrophic Cardiomyopathy; Restrictive Cardiomyopathy
Intervention:
Sponsors: University of Miami; University of Miami; New England Research Institutes; Children's Hospital Medical Center, Cincinnati; Washington University School of Medicine; Children's Hospital of Philadelphia; Columbia University; Children's Hospital Boston; Ann & Robert H Lurie Children's Hospital of Chicago; Primary Children's Medical Center; Monroe Carell Jr Children's Hospital at Vanderbilt; Stollery Children's Hospital
Recruiting - verified June 2013 - Conditions: Dilated Cardiomyopathy; Hypertrophic Cardiomyopathy
Intervention:
Sponsors: University of Miami; University of Miami; New England Research Institutes; Washington University School of Medicine; Children's Hospital Boston; Columbia University; Children's Hospital of Philadelphia; Ann & Robert H Lurie Children's Hospital of Chicago; Primary Children's Medical Center; Monroe Carell Jr Children's Hospital at Vanderbilt; Stollery Children's Hospital; Children's Hospital Medical Center, Cincinnati; Montefiore Medical Center
Not yet recruiting - verified June 2013 - Condition: Hodgkin Disease
Interventions: Drug: brentuximab vedotin; Drug: bendamustine
Sponsors: Seattle Genetics, Inc.; Seattle Genetics, Inc.
Recruiting - verified June 2013 - Condition: Idiopathic Pulmonary Fibrosis
Interventions: Drug: lebrikizumab; Drug: placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Not yet recruiting - verified June 2013 - Condition: Achalasia
Intervention: Procedure: Endoscopic Esophageal Myotomy
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital
Recruiting - verified June 2013 - Condition: Smoking Cessation
Interventions: Behavioral: Brief Treatment (BT); Behavioral: Intensive Treatment (IT)
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; National Cancer Institute (NCI); National Institutes of Health (NIH)
Not yet recruiting - verified June 2013 - Condition: Alzheimer Disease
Intervention:
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; Alzheimer's Association
Not yet recruiting - verified June 2013 - Condition: Overactive Bladder
Interventions: Drug: dexmecamylamine; Drug: Placebo
Sponsors: Targacept Inc.; Targacept Inc.
Recruiting - verified June 2013 - Condition: Parkinson's Disease
Intervention:
Sponsors: Brigham and Women's Hospital; Brigham and Women's Hospital; National Institute of Neurological Disorders and Stroke (NINDS); Harvard Medical School
Recruiting - verified June 2013 - Condition: Breast Cancer
Interventions: Drug: LEE011; Drug: Letrozole; Drug: BYL719
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified June 2013 - Conditions: T-Cell Lymphoma; Relapsed T-Cell Lymphoma; Refractory T-Cell Lymphoma
Interventions: Drug: PEG-L-asparaginase; Drug: Dexamethasone acetate
Sponsors: Dana-Farber Cancer Institute; Dana-Farber Cancer Institute; Sigma Tau Pharmaceuticals, Inc.
Not yet recruiting - verified June 2013 - Condition: Breast Cancer
Interventions: Drug: GDC-0032; Drug: GDC-0032; Drug: Docetaxel; Drug: Paclitaxel
Sponsors: Genentech; Genentech
Recruiting - verified May 2013 - Comparison of Reverse Remodeling and PVI Versus CFAE and/or Linear Lesions and PVI for Persistent AFCondition: Persistent Atrial Fibrillation
Intervention: Procedure: Ablation
Sponsors: Valley Health System; Valley Health System; Massachusetts General Hospital; Long Island Jewish Hospital; State Research Institute of Circulation Pathology
Recruiting - verified June 2013 - Condition: Pregnancy
Interventions: Device: Lighting1; Device: Lighting2
Sponsors: Brigham and Women's Hospital; Brigham and Women's Hospital; Harvard University Milton Fund
Not yet recruiting - verified May 2013 - Conditions: Atherosclerosis; Atherosclerotic Plaque; Carotid Stenosis
Intervention: Drug: Indocyanine green
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital
Recruiting - verified June 2013 - Condition: Bilateral Hearing Loss for Causes Other Than Tumors
Intervention: Device: Nucleus 24 Auditory Brainstem Implant (ABI)
Sponsors: Massachusetts Eye and Ear Infirmary; Massachusetts Eye and Ear Infirmary
Recruiting - verified May 2013 - Conditions: Lymphoblastic Leukemia, Acute, Childhood; Myelogenous Leukemia, Acute, Childhood
Interventions: Drug: Azacitidine; Drug: Fludarabine; Drug: Cytarabine
Sponsors: Therapeutic Advances in Childhood Leukemia Consortium; Therapeutic Advances in Childhood Leukemia Consortium; Gateway for Cancer Research; USC/Norris Comprehensive Cancer Center
Not yet recruiting - verified May 2013 - Condition: Atopic Dermatitis
Interventions: Drug: Dupilumab (REGN668/ SAR231893); Drug: Placebo
Sponsors: Regeneron Pharmaceuticals; Regeneron Pharmaceuticals; Sanofi
Recruiting - verified May 2013 - Conditions: Major Depressive Disorder; Depression, Unipolar; Recurrence; Relapse
Interventions: Drug: Naltrexone; Drug: Placebo capsule
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital
Not yet recruiting - verified June 2013 - Conditions: Full Iris Defects; Partial Iris Defects
Intervention: Device: Artificial Iris (CustomFlex)
Sponsors: HumanOptics AG; HumanOptics AG
Not yet recruiting - verified June 2013 - Conditions: Pulmonary Hypertension; Chronic Obstructive Pulmonary Disease (COPD)
Interventions: Drug: Tadalafil; Drug: placebo
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs
Not yet recruiting - verified May 2013 - Condition: Hypovitaminosis D
Interventions: Dietary Supplement: Cholecalciferol; Dietary Supplement: Placebo
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; BioTech Pharmacal
Not yet recruiting - verified May 2013 - Condition: Hypertrophic Scars
Intervention: Device: Fraxel Repair - Fractional Laser treatment
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital
Recruiting - verified June 2013 - Condition: Glioblastoma
Intervention: Device: C-11 methionine PET
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital
Not yet recruiting - verified May 2013 - Condition: Ewing Sarcoma
Interventions: Drug: Olaparib; Drug: Temozolomide
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital
Not yet recruiting - verified May 2013 - Condition: Hepatitis C
Intervention: Drug: SOF in combination with GS-5816
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified June 2013 - Conditions: Contiguous Stage II Adult Diffuse Large Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma; Stage III Adult Diffuse Large Cell Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma
Interventions: Drug: lenalidomide; Biological: rituximab; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: vincristine sulfate; Drug: prednisone; Other: laboratory biomarker analysis; Procedure: positron emission tomography
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Not yet recruiting - verified June 2013 - Condition: Obesity
Interventions: Dietary Supplement: Lactobacillus Rhamnosus GG; Dietary Supplement: Placebo
Sponsors: Tufts Medical Center; Tufts Medical Center
Not yet recruiting - verified June 2013 - Condition: Williams Syndrome
Intervention:
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital
Not yet recruiting - verified May 2013 - Condition: Non-Small Cell Lung Cancer
Intervention: Drug: MPDL3280A
Sponsors: Genentech; Genentech
Recruiting - verified May 2013 - Condition: Amyotrophic Lateral Sclerosis
Intervention: Drug: GM604
Sponsors: Genervon Biopharmaceuticals, LLC; Genervon Biopharmaceuticals, LLC; Columbia University; Massachusetts General Hospital
Not yet recruiting - verified June 2013 - Conditions: Painful Lumbar Radiculopathy; Sciatica; Radiculopathy
Interventions: Drug: BG00010; Drug: Placebo
Sponsors: Biogen Idec; Biogen Idec; Biogen Idec Research Ltd.
Not yet recruiting - verified June 2013 - Condition: Sporadic Amyotrophic Lateral Sclerosis
Interventions: Drug: Mexiletine; Drug: Placebo
Sponsors: University of Washington; University of Washington
Not yet recruiting - verified May 2013 - Conditions: Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma
Interventions: Drug: bortezomib; Drug: lenalidomide; Drug: dexamethasone; Drug: carfilzomib; Procedure: quality-of-life assessment; Other: laboratory biomarker analysis
Sponsors: Eastern Cooperative Oncology Group; Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Not yet recruiting - verified May 2013 - Condition: Attention Deficit Hyperactivity Disorder
Intervention: Drug: Naltrexone
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital
Not yet recruiting - verified June 2013 - Condition: Chronic Hepatitis C Virus
Interventions: Drug: Sofosbuvir/Ledipasvir 400/90 mg; Drug: Ribavirin
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified May 2013 - Condition: Breast Cancer
Interventions: Drug: Trastuzumab; Drug: Paclitaxel; Drug: Trastuzumab emtansine
Sponsors: Dana-Farber Cancer Institute; Dana-Farber Cancer Institute
Recruiting - verified May 2013 - Condition: Human Immunodeficiency Virus
Intervention: Drug: Coformulated Elivitegravir (150mg), Combicistat (150mg), Emtricitabine (200mg), Tenofovir DF (300mg)
Sponsors: Fenway Community Health; Kenneth H. Mayer, MD; Gilead Sciences
Recruiting - verified June 2013 - Conditions: Hyperphagia; Prader-Willi Syndrome
Intervention: Device: tDCS
Sponsors: University of Kansas; Merlin G. Butler, MD, PhD; Prader-Willi Syndrome Association USA; Harvard Medical School
Recruiting - verified May 2013 - Condition: Coronary Artery Bypass Grafting
Intervention: Procedure: Vein Harvesting Procedures
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs
Not yet recruiting - verified June 2013 - Condition: Renal Cell Carcinoma
Interventions: Drug: Tivozanib; Drug: Gemcitabine
Sponsors: Dana-Farber Cancer Institute; Dana-Farber Cancer Institute
Not yet recruiting - verified June 2013 - Condition: Non-small Cell Lung Cancer (NSCLC)
Intervention: Device: Endocutter
Sponsors: Ethicon Endo-Surgery; Ethicon Endo-Surgery
Recruiting - verified June 2013 - Condition: Atrial Fibrillation
Intervention:
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2013 - Condition: Lung Cancer
Intervention: Drug: Sunitinib
Sponsors: Dana-Farber Cancer Institute; Dana-Farber Cancer Institute
Recruiting - verified May 2013 - Condition: Pulmonary Hypertension
Interventions: Drug: Ranolazine; Drug: Placebo
Sponsors: University of Pennsylvania; University of Pennsylvania; The Cardiovascular Medical Research and Education Fund; Brigham and Women's Hospital; University of Maryland; Yale University
Not yet recruiting - verified June 2013 - Conditions: Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
Interventions: Drug: Bendamustine; Drug: Rituximab
Sponsors: Dartmouth-Hitchcock Medical Center; Dartmouth-Hitchcock Medical Center; National Cancer Institute (NCI)
Recruiting - verified May 2013 - Condition: Breast Cancer
Intervention: Drug: Eribulin
Sponsors: Dana-Farber Cancer Institute; Dana-Farber Cancer Institute
Recruiting - verified June 2013 - Condition: Relapsed or Refractory Mantle Cell Lymphoma
Intervention: Drug: Ibrutinib
Sponsors: Janssen Biotech, Inc.; Janssen Biotech, Inc.; Pharmacyclics
Recruiting - verified June 2013 - Condition: Acute Myelogenous Leukemia
Interventions: Drug: Brentuximab Vedotin; Drug: Mitoxantrone; Drug: Etoposide; Drug: Cytarabine
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital
Recruiting - verified May 2013 - Conditions: Gastrinoma; Glucagonoma; Insulinoma; Islet Cell Carcinoma; Pancreatic Polypeptide Tumor; Recurrent Islet Cell Carcinoma; Somatostatinoma
Interventions: Drug: temozolomide; Drug: capecitabine; Other: laboratory biomarker analysis
Sponsors: Eastern Cooperative Oncology Group; Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Not yet recruiting - verified October 2012 - Conditions: Estrogen Receptor-positive Breast Cancer; Musculoskeletal Complications; Progesterone Receptor-positive Breast Cancer; Recurrent Breast Cancer; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer
Interventions: Drug: anastrozole; Other: questionnaire administration; Other: laboratory biomarker analysis; Other: pharmacogenomic studies
Sponsors: Eastern Cooperative Oncology Group; Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Not yet recruiting - verified May 2013 - Conditions: Muscular Dystrophy, Duchenne; Muscular Dystrophies; Muscular Disorders, Atrophic; Muscular Diseases; Musculoskeletal Diseases; Neuromuscular Diseases; Nervous System Diseases; Genetic Diseases, X-Linked; Genetic Diseases, Inborn
Interventions: Drug: Ataluren; Drug: Placebo
Sponsors: PTC Therapeutics; PTC Therapeutics
Recruiting - verified April 2013 - Condition: Cognitive Impairment
Interventions: Behavioral: Cognitive Screen; Behavioral: Mini-Cog
Sponsors: Brigham and Women's Hospital; Brigham and Women's Hospital
Recruiting - verified May 2013 - Conditions: HIV; HIV Infections
Interventions: Drug: elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide; Drug: E/C/F/TDF, EFV/FTC/TDF, ritonavir + atazanavir + FTC/TDF, or GS-9350 + atazanavir + FTC/TDF
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified May 2013 - Condition: Phenylketonuria
Intervention: Drug: BMN 165
Sponsors: BioMarin Pharmaceutical; BioMarin Pharmaceutical
Recruiting - verified June 2013 - Condition: Hypogonadism
Interventions: Drug: Testosterone Solution; Drug: Placebo Solution
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified June 2013 - Condition: Non Small Cell Lung Cancer
Intervention: Drug: Ponatinib
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital
Not yet recruiting - verified May 2013 - Condition: Esophageal Cancer
Intervention: Procedure: Near Infrared Imaging (NIR) for lymphatic mapping
Sponsors: Dana-Farber Cancer Institute; Dana-Farber Cancer Institute
Recruiting - verified June 2013 - Condition: Myeloma
Interventions: Drug: Pomalidomide; Drug: Melphalan; Drug: Dexamethasone; Behavioral: Questionnaires
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Celgene Corporation; Tufts Medical Center
Not yet recruiting - verified May 2013 - Condition: Cystic Fibrosis, Homozygous for the F508del CFTR Mutation
Interventions: Drug: Ivacaftor; Drug: Lumacaftor; Drug: Ivacaftor Placebo; Drug: Lumacaftor Placebo
Sponsors: Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals Incorporated
Recruiting - verified June 2013 - Condition: Healthy
Interventions: Drug: PF-05175157; Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013 - Condition: Postmenopausal Osteoporosis
Interventions: Drug: AMG 785; Drug: Teriparatide (TPTD)
Sponsors: Amgen; Amgen
Recruiting - verified June 2013 - Conditions: Type 2 Diabetes; Comparative Effectiveness of Glycemia-lowering Medications
Interventions: Drug: Sulfonylurea (glimepiride); Drug: DPP-4 inhibitor (sitagliptin); Drug: GLP-1 receptor agonist (liraglutide); Drug: Insulin (glargine)
Sponsors: GRADE Study Group; GRADE Study Group; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Becton, Dickinson and Company; Bristol-Myers Squibb; Merck; Novo Nordisk; Hoffmann-La Roche; Sanofi
Recruiting - verified May 2013 - Conditions: Burkitt Lymphoma; Precursor B-cell Lymphoblastic Leukemia-Lymphoma
Intervention: Drug: SGN-CD19A
Sponsors: Seattle Genetics, Inc.; Seattle Genetics, Inc.
Recruiting - verified May 2013 - Condition: Giant Cell Arteritis
Interventions: Drug: tocilizumab [RoActemra/Actemra]; Drug: tocilizumab [RoActemra/Actemra]; Drug: tocilizumab placebo; Drug: prednisone; Drug: prednisone placebo; Drug: tocilizumab [RoActemra/Actemra]
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Not yet recruiting - verified June 2013 - Condition: Hypertension, Pulmonary
Intervention: Drug: Riociguat (BAY 63-2521)
Sponsors: Bayer; Bayer
Available - verified May 2013 - Condition: Advanced or Metastatic Melanoma
Interventions: Biological: Nivolumab; Biological: Ipilimumab
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified May 2013 - Condition: Safety of Neosaxitoxin in Healthy Adult Male Volunteers
Interventions: Drug: Neosaxitoxin (NeoSTX) in saline; Drug: NeoSTX with 0.2% bupivacaine; Other: Placebo
Sponsors: Children's Hospital Boston; Children's Hospital Boston
Recruiting - verified May 2013 - Condition: HIV Infections
Interventions: Biological: DNA-HIV-PT123 vaccine; Biological: NYVAC-HIV-PT1 vaccine; Biological: NYVAC-HIV-PT4 vaccine; Biological: Placebo for DNA-HIV-PT123 vaccine; Biological: Placebo for NYVAC-HIV-PT1 vaccine; Biological: Placebo for NYVAC-HIV-PT4 vaccine
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified June 2013 - Condition: Depression
Intervention: Drug: Testosterone
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; Lawley Pharmaceuticals
Not yet recruiting - verified June 2013 - Condition: HIV Infections
Intervention: Drug: Raltegravir
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting - verified June 2013 - Condition: Acute Kidney Injury
Interventions: Drug: ABT-719; Drug: Placebo
Sponsors: AbbVie; AbbVie
Recruiting - verified May 2013 - Condition: Hemophilia A
Intervention: Biological: BAY94-9027
Sponsors: Bayer; Bayer
Not yet recruiting - verified May 2013 - Conditions: Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell
Interventions: Drug: cyclophosphamide; Drug: doxorubicin; Drug: vincristine; Drug: prednisone; Drug: brentuximab vedotin
Sponsors: Seattle Genetics, Inc.; Seattle Genetics, Inc.; Millennium Pharmaceuticals, Inc.
Recruiting - verified June 2013 - Condition: Idiopathic Parkinson's Disease
Interventions: Drug: CVT-301; Drug: Placebo
Sponsors: Civitas Therapeutics; Civitas Therapeutics
Recruiting - verified June 2013 - Condition: Idiopathic Pulmonary Fibrosis
Interventions: Drug: Simtuzumab (GS-6624); Drug: Placebo
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified June 2013 - Condition: Carcinoma, Hepatocellular
Interventions: Drug: Regorafenib (BAY73-4506); Drug: Placebo
Sponsors: Bayer; Bayer
Recruiting - verified May 2013 - Condition: Acute Respiratory Distress Syndrome
Intervention: Biological: Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells
Sponsors: University of California, San Francisco; Michael A. Matthay; National Heart, Lung, and Blood Institute (NHLBI); Massachusetts General Hospital
Recruiting - verified May 2013 - Condition: Migraine
Intervention: Biological: ALD403
Sponsors: Alder Biopharmaceuticals, Inc.; Alder Biopharmaceuticals, Inc.
Recruiting - verified May 2013 - Condition: Advanced Solid Tumor
Interventions: Drug: LDE225; Drug: Wafarin; Drug: Bupropion
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2013 - Conditions: Transplantation; Organ Transplantation; Heart Transplantation
Interventions: Drug: Bortezomib; Procedure: Plasmapheresis on days 0, 1 and 2.
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID); Clinical Trials in Organ Transplantation (CTOT)
Recruiting - verified June 2013 - Condition: Obesity
Interventions: Device: Aspiration Therapy (AspireAssist); Behavioral: Lifestyle Therapy
Sponsors: Aspire Bariatrics, Inc.; Aspire Bariatrics, Inc.; Boston Medical Center; Brigham and Women's Hospital; Cornell University; Howard University; Mayo Clinic; Northwestern University; St. Mary Medical Center; San Diego Veterans Healthcare System; University of Pennsylvania; Washington University School of Medicine
Recruiting - verified May 2013 - Conditions: Amnestic Mild Cognitive Impairment; Alzheimer's Disease
Interventions: Drug: Insulin (Humulin® R U-100); Drug: Placebo
Sponsors: Alzheimer's Disease Cooperative Study (ADCS); Alzheimer's Disease Cooperative Study (ADCS)
Not yet recruiting - verified June 2013 - Condition: Colorectal Cancer
Interventions: Drug: bevacizumab [Avastin]; Drug: leucovorin; Drug: 5-fluorouracil; Drug: irinotecan; Drug: oxaliplatin; Drug: capecitabine [Xeloda]; Drug: fluoropyrimidine-based chemotherapy
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified June 2013 - Conditions: Neurofibromatosis Type 2; Progressive Vestibular Schwannomas
Intervention: Drug: Bevacizumab
Sponsors: University of Alabama at Birmingham; University of Alabama at Birmingham; Genentech
Recruiting - verified May 2013 - Condition: Clinical Safety of the ProMRI Pacemaker System When Used Under Specific MRI Conditions.
Interventions: Device: Patients with a ProMRI Pacemaker System; Other: Magnetic Resonance Imaging (MRI) scan
Sponsors: Biotronik, Inc.; Biotronik, Inc.
Recruiting - verified May 2013 - Condition: Solid Tumor With p53 Wild Status
Intervention: Drug: CGM097
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified June 2013 - Conditions: Cholesterol Ester Storage Disease (CESD); Lysosomal Acid Lipase Deficiency
Interventions: Drug: SBC-102 [sebelipase alfa] (1 mg/kg); Drug: Placebo
Sponsors: Synageva BioPharma Corp.; Synageva BioPharma Corp.
Recruiting - verified June 2013 - Condition: Melanoma
Intervention: Biological: WDVAX
Sponsors: Dana-Farber Cancer Institute; Dana-Farber Cancer Institute
Recruiting - verified June 2013 - Condition: Fecal Analysis
Intervention: Dietary Supplement: ProNutrients Probiotic
Sponsors: Pfizer; Pfizer
Recruiting - verified June 2013 - Condition: Renal Cell Carcinoma
Intervention: Drug: ASONEP
Sponsors: Lpath, Inc.; Lpath, Inc.
Recruiting - verified June 2013 - Condition: Peanut Allergy
Interventions: Drug: Peanut Flour; Drug: Oat Flour
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified June 2013 - Condition: Malignant Solid Tumor - Malignant Nervous System Neoplasm
Intervention: Drug: Cabazitaxel (XRP6258)
Sponsors: Sanofi; Sanofi
Recruiting - verified June 2013 - Condition: Cystic Fibrosis
Interventions: Drug: Vancomycin inhalation powder; Drug: Placebo inhalation powder
Sponsors: Savara Inc.; Savara Inc.; Synteract, Inc.
Recruiting - verified June 2013 - Condition: Cystic Fibrosis
Interventions: Drug: N6022; Drug: Normal saline
Sponsors: N30 Pharmaceuticals, Inc.; N30 Pharmaceuticals, Inc.
Recruiting - verified June 2013 - Condition: Postherpetic Neuralgia
Interventions: Drug: Z160; Drug: Placebo
Sponsors: Zalicus; Zalicus
Recruiting - verified June 2013 - Condition: Malignant Rhabdoid Tumors (MRT), Neuroblastoma
Intervention: Drug: LEE011
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified June 2013 - Conditions: Acute Myeloid Leukemia (AML); Myelodysplastic Syndrome (MDS)
Intervention: Drug: Treosulfan
Sponsors: Center for International Blood and Marrow Transplant Research; Center for International Blood and Marrow Transplant Research; National Marrow Donor Program; Resource for Clinical Investigation in Blood and Marrow Transplantation (RCI BMT); Pediatric Blood and Marrow Transplant Consortium; St. Baldrick's Foundation; medac GmbH
Not yet recruiting - verified May 2013 - Condition: Eisenmenger Syndrome
Interventions: Drug: Macitentan 10 mg, oral tablet, to be taken once daily.; Drug: Matching placebo oral tablet, to be taken once daily.
Sponsors: Actelion; Actelion
Recruiting - verified June 2013 - Condition: Familial Amyloid Polyneuropathy
Interventions: Drug: ISIS TTR Rx; Drug: Placebo
Sponsors: Isis Pharmaceuticals; Isis Pharmaceuticals; GlaxoSmithKline
Recruiting - verified June 2013 - Conditions: Relapsed Acute Lymphoblastic Leukemia; Relapsed Acute Myelogenous Leukemia
Intervention: Drug: GNKG168
Sponsors: Therapeutic Advances in Childhood Leukemia Consortium; Therapeutic Advances in Childhood Leukemia Consortium
Recruiting - verified May 2013 - Condition: Non Small Cell Lung Cancer
Intervention: Drug: Afatinib
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; National Comprehensive Cancer Network
Recruiting - verified May 2013 - Condition: Spinal Muscular Atrophy (SMA)
Intervention:
Sponsors: Ohio State University; Ohio State University; National Institute of Neurological Disorders and Stroke (NINDS); Families of SMA; Massachusetts General Hospital; University of Iowa
Recruiting - verified June 2013 - Condition: Venous Leg Ulcers
Interventions: Biological: HP802-247; Biological: Vehicle
Sponsors: Healthpoint; Healthpoint
Recruiting - verified May 2013 - Condition: Type 2 Diabetes
Interventions: Drug: Cholecalciferol; Drug: Placebo
Sponsors: Tufts Medical Center; Tufts Medical Center; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified May 2013 - Condition: Unresectable or Metastatic Melanoma
Interventions: Biological: BMS-936558; Drug: Dacarbazine; Drug: Carboplatin; Drug: Paclitaxel
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified May 2013 - Condition: Systemic Infection
Intervention: Drug: Antibiotic
Sponsors: Duke University; Phillip Brian Smith
Recruiting - verified June 2013 - Conditions: Epilepsy; Pregnancy
Intervention:
Sponsors: Emory University; Emory University; The EMMES Corporation
Recruiting - verified June 2013 - Condition: Non Small Cell Lung Cancer
Intervention: Device: Circulating tumor cell chip
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; Dana-Farber Cancer Institute; Memorial Sloan-Kettering Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2013 - Condition: Parkinson's Disease
Interventions: Drug: Rasagiline; Drug: Placebo
Sponsors: Teva Pharmaceutical Industries; Teva Branded Pharmaceutical Products, R&D Inc.
Recruiting - verified June 2013 - Condition: Squamous Cell Non-small Cell Lung Cancer
Intervention: Drug: Nivolumab (BMS-936558)
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified May 2013 - Condition: Small Cell Lung Carcinoma
Interventions: Drug: LY2940680; Drug: Carboplatin; Drug: Etoposide; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified June 2013 - Condition: CANCER,NOS
Interventions: Drug: BMS-986015 (ANTI-KIR); Drug: BMS-936558 (ANTI-PD1)
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified June 2013 - Condition: Binge Eating Disorder
Interventions: Drug: SPD489 (Lisdexamfetamine dimesylate); Drug: Placebo
Sponsors: Shire Development LLC; Shire Development LLC
Recruiting - verified May 2013 - Condition: Lupus Nephritis
Interventions: Biological: BMS-188667; Drug: Mycophenolate mofetil; Drug: Prednisone; Biological: Placebo matching with BMS-188667
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified June 2013 - Condition: Cardiovascular Disease, Diabetes Mellitus, Type 2
Interventions: Drug: aleglitazar; Drug: Placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified June 2013 - Condition: Atrial Fibrillation
Interventions: Drug: rivaroxaban; Drug: uninterrupted vitamin K antagonist (VKA)
Sponsors: Janssen Scientific Affairs, LLC; Janssen Scientific Affairs, LLC
Recruiting - verified June 2013 - Condition: Multiple Myeloma
Interventions: Drug: DKN-01 300 mg; Drug: DKN-01 600 mg; Drug: Standard of Care
Sponsors: Dekkun Corporation; Dekkun Corporation
Recruiting - verified May 2013 - Conditions: Cigarette Smoking; Tobacco Smoking; Tobacco Use Disorder
Interventions: Behavioral: Extended Care; Behavioral: Standard Care
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; University of Pittsburgh; North Shore Medical Center
Recruiting - verified June 2013 - Conditions: Follicular Thyroid Cancer; Insular Thyroid Cancer; Papillary Thyroid Cancer; Recurrent Thyroid Cancer
Interventions: Drug: dabrafenib; Drug: trametinib; Other: Correlative Studies
Sponsors: Ohio State University Comprehensive Cancer Center; Manisha Shah; National Comprehensive Cancer Network
Recruiting - verified June 2013 - Condition: Cystic Fibrosis
Interventions: Drug: dornase alfa [Pulmozyme]; Drug: dornase alfa [Pulmozyme]
Sponsors: Genentech; Genentech
Recruiting - verified May 2013 - Condition: Bacterial Vaccines
Interventions: Procedure: Blood sampling; Other: Stool sample collection
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified March 2013 - Condition: Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee
Interventions: Drug: GRT6005 Low-Dose Range; Drug: GRT6005 High-Dose Range; Drug: Placebo; Drug: Oxycodone CR
Sponsors: Forest Laboratories; Forest Laboratories; Grünenthal GmbH
Recruiting - verified May 2013 - Condition: Amyotrophic Lateral Sclerosis
Interventions: Drug: CK-2017357; Other: Placebo tablets
Sponsors: Cytokinetics; Cytokinetics
Recruiting - verified June 2013 - Condition: Medulloblastoma
Interventions: Drug: LDE225; Drug: TMZ
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified June 2013 - Condition: Primary Amyloidosis
Intervention: Drug: NEOD001
Sponsors: Onclave Therapeutics Limited, a wholly-owned subsidiary of Prothena Corporation plc; Onclave Therapeutics Limited, a wholly-owned subsidiary of Prothena Corporation plc
Recruiting - verified May 2013 - Condition: Tuberous Sclerosis Complex-associated Refractory Seizures
Interventions: Drug: RAD001; Drug: Placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2013 - Condition: Atrial Fibrillation
Intervention: Drug: Non-coumadin Oral Anticoagulant
Sponsors: Northwestern University; Northwestern University; National Heart, Lung, and Blood Institute (NHLBI); Medtronic
Recruiting - verified May 2013 - Conditions: Acquired Immunodeficiency Syndrome; HIV Infections
Interventions: Drug: elvitegravir/cobicistat/emtricitabine/tenofovir df; Drug: ritonavir + atazanavir + emtricitabine/tenofovir df
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified June 2013 - Condition: Hypercholesterolemia
Interventions: Drug: alirocumab (REGN727/ SAR236553); Drug: Active Comparator 1 (ezetimibe); Drug: Active Comparator 2 (atorvastatin); Other: Placebo 1 (placebo for ezetimibe atorvastatin); Other: Placebo 2 [alirocumab (REGN727/ SAR236553)]
Sponsors: Regeneron Pharmaceuticals; Regeneron Pharmaceuticals; Sanofi
Recruiting - verified May 2013 - Condition: Alzheimer's Disease
Intervention: Drug: florbetapir (18F)
Sponsors: Avid Radiopharmaceuticals; Avid Radiopharmaceuticals; Eli Lilly and Company
Recruiting - verified June 2013 - Condition: Measles, Mumps and Rubella Diseases
Interventions: Biological: GSK Biologicals measles, mumps and rubella vaccine live (GSK 209762).; Biological: Merck & Co., Inc.'s M-M-R®II (also called M-M-R Vax Pro®), combined measles-mumps-rubella virus vaccine.; Biological: Varivax® (Merck & Co., Inc.); Biological: Havrix®; Biological: Prevnar 13® (Pfizer Inc.)
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2013 - Condition: Melanoma
Intervention:
Sponsors: MELA Sciences, Inc.; MELA Sciences, Inc.
Recruiting - verified June 2013 - Condition: Multiple Sclerosis (MS)
Interventions: Drug: Laquinimod 0.6 mg; Drug: Matching Placebo; Drug: Laquinimod 1.2 mg
Sponsors: Teva Pharmaceutical Industries; Teva Pharmaceutical Industries
Recruiting - verified May 2013 - Condition: Malignant Melanoma
Intervention: Biological: Ipilimumab
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified June 2013 - Condition: Multiple Myeloma
Intervention: Drug: PRLX 93936
Sponsors: Prolexys Pharmaceuticals; Prolexys Pharmaceuticals
Recruiting - verified May 2013 - Conditions: PIK3CA Mutated Advanced Solid Tumors,; PIK3CA Amplified Advanced Solid Tumors
Interventions: Drug: BYL719; Drug: AMG 479
Sponsors: Novartis; Novartis Pharmaceuticals; Amgen
Recruiting - verified June 2013 - Condition: Clostridium Difficile-Associated Diarrhea (CDAD)
Interventions: Drug: fidaxomicin; Drug: placebo
Sponsors: Optimer Pharmaceuticals; Optimer Pharmaceuticals
Recruiting - verified June 2013 - Condition: Chronic Anal Fissures
Interventions: Drug: VEN 307; Drug: Placebo
Sponsors: Ventrus Biosciences, Inc; Ventrus Biosciences, Inc
Recruiting - verified June 2013 - Condition: Moderate to Severe Plaque Psoriasis
Interventions: Drug: 210 mg brodalumab; Drug: 140 mg brodalumab; Drug: ustekinumab; Drug: placebo
Sponsors: Amgen; Amgen
Recruiting - verified June 2013 - Condition: Lymphoma, B-Cell, Lymphoma, Follicular
Interventions: Drug: DCDT2980S; Drug: DCDS4501A; Drug: rituximab [MabThera/Rituxan]
Sponsors: Genentech; Genentech
Recruiting - verified June 2013 - Conditions: Hepatitis C; Cirrhosis; Portal Hypertension; With or Without Liver Decompensation
Interventions: Drug: GS-7977; Drug: Ribavirin
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified May 2013 - Condition: Carotid Artery Disease
Intervention: Device: MICHI NPS+f
Sponsors: Silk Road Medical; Silk Road Medical
Recruiting - verified June 2013 - Conditions: Prostate Cancer; Metastatic Castrate-Resistant Prostate Cancer; PSA
Interventions: Drug: OGX-427; Drug: Abiraterone Acetate; Drug: Prednisone
Sponsors: Hoosier Oncology Group; Hoosier Oncology Group; OncoGenex Technologies
Recruiting - verified May 2013 - Condition: Non-Small Cell Lung Cancer
Intervention: Drug: LDK378
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified June 2013 - Condition: Non-Small Cell Lung Cancer
Intervention: Drug: LDK378
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified June 2013 - Condition: Cardiac Amyloidosis
Intervention: Drug: F-18 florbetapir PET
Sponsors: Brigham and Women's Hospital; Brigham and Women's Hospital; Amyloid Foundation
Recruiting - verified June 2013 - Condition: Hypovitaminosis D
Interventions: Drug: 100, 000 IU cholecalciferol; Drug: Placebo
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; BioTech Pharmacal
Recruiting - verified May 2013 - Condition: Non-Squamous Cell Non-small Cell Lung Cancer
Interventions: Biological: BMS-936558; Drug: Docetaxel
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified May 2013 - Condition: Pain
Interventions: Other: Acupuncture or Sham Acupuncture; Other: Gabapentin or Placebo
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; National Center for Complementary and Alternative Medicine (NCCAM)
Recruiting - verified May 2013 - Condition: Carcinoid Syndrome
Interventions: Drug: Telotristat etiprate tablets (250 mg); Drug: Placebo tablets
Sponsors: Lexicon Pharmaceuticals; Lexicon Pharmaceuticals
Recruiting - verified May 2013 - Condition: Neoplasms, Brain
Interventions: Drug: Dabrafenib 3 mg/kg; Drug: Dabrafenib 3.75 mg/kg; Drug: Dabrafenib 4.5 mg/kg; Drug: Dabrafenib 1.5 mg/kg; Drug: Dabrafenib 2.25 mg/kg; Drug: Dabrafenib (Final selected dose from Part 1)
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2013 - Conditions: Renal Artery Stenosis; Hypertension, Renovascular
Intervention: Device: iCAST™ Rx Stent System
Sponsors: Atrium Medical Corporation; Atrium Medical Corporation
Recruiting - verified May 2013 - Condition: Neoplasm Malignant-
Interventions: Drug: SAR260301; Drug: Vemurafenib
Sponsors: Sanofi; Sanofi
Recruiting - verified June 2013 - Condition: Primary Sclerosing Cholangitis (PSC)
Interventions: Biological: GS-6624; Biological: Placebo
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified May 2013 - Condition: Non-Alcoholic Steatohepatitis (NASH)
Interventions: Biological: GS-6624 75 mg; Biological: GS-6624 125 mg; Biological: Placebo
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified May 2013 - Condition: Severe Aortic Stenosis
Intervention: Device: Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI)
Sponsors: Medtronic Cardiovascular; Medtronic Cardiovascular
Recruiting - verified May 2013 - Condition: Hemangioma
Interventions: Drug: topical timolol maleate; Device: Pulsed dye laser
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital
Recruiting - verified June 2013 - Condition: Breast Neoplasms
Intervention: Drug: neratinib
Sponsors: Washington University School of Medicine; Washington University School of Medicine
Recruiting - verified June 2013 - Condition: Transplantation, Cytomegalovirus Infections
Intervention:
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified June 2013 - Conditions: Malignant Peripheral Nerve Sheath Tumors; MPNST; Sarcoma
Interventions: Drug: everolimus; Drug: bevacizumab
Sponsors: Sarcoma Alliance for Research through Collaboration; Sarcoma Alliance for Research through Collaboration; Novartis Pharmaceuticals; Genentech; Department of Defense
Recruiting - verified June 2013 - Condition: Anal Cancer
Intervention: Biological: Advaxis
Sponsors: Brown University; Brown University; Rhode Island Hospital; The Miriam Hospital; Montefiore Medical Center; M.D. Anderson Cancer Center; Boston Medical Center; Ohio State University Comprehensive Cancer Center; University of Pennsylvania
Recruiting - verified June 2013 - Condition: Acute Coronary Syndrome
Interventions: Drug: SAR236553 (REGN727); Other: placebo
Sponsors: Sanofi; Sanofi; Regeneron Pharmaceuticals
Recruiting - verified June 2013 - Condition: Relapsed or Refractory Systemic Light Chain Amyloidosis
Interventions: Drug: MLN9708; Drug: Dexamethasone; Drug: Melphalan; Drug: Cyclophosphamide; Drug: Thalidomide; Drug: Lenalidomide
Sponsors: Millennium Pharmaceuticals, Inc.; Millennium Pharmaceuticals, Inc.
Recruiting - verified June 2013 - Condition: Binge Eating Disorder
Intervention: Drug: Lisdexamfetamine dimesylate
Sponsors: Shire Development LLC; Shire Development LLC
Recruiting - verified June 2013 - Condition: Fibrosing Colonopathy in Patients With Cystic Fibrosis
Interventions: Biological: CREON; Biological: ZENPEP; Biological: ULTRESA; Biological: PANCREAZE; Biological: other non-sponsor pancreatic enzyme replacement therapy; Other: No pancreatic enzyme replacement therapy
Sponsors: AbbVie; AbbVie (prior sponsor, Abbott); Aptalis Pharma; Cystic Fibrosis Foundation; Janssen Research & Development, LLC
Recruiting - verified May 2013 - Condition: Venous Leg Ulcers
Interventions: Biological: HP-802-247; Biological: Vehicle
Sponsors: Healthpoint; Healthpoint; Smith & Nephew, Inc.
Recruiting - verified June 2013 - Condition: Treatment Resistant Depression
Interventions: Device: Low Frequency Magnetic Stimulation (LFMS); Device: Sham LFMS
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; National Institute of Mental Health (NIMH); Yale University; Mount Sinai School of Medicine; University of Texas Southwestern Medical Center; University of Alabama at Birmingham; Emory University
Recruiting - verified June 2013 - Condition: Lumbosacral Radiculopathy
Interventions: Drug: z160; Drug: Placebo
Sponsors: Zalicus; Zalicus
Recruiting - verified June 2013 - Condition: Systemic Sclerosis
Interventions: Drug: SAR100842; Drug: Placebo
Sponsors: Sanofi; Sanofi
Recruiting - verified June 2013 - Condition: Chronic Myeloid Leukemia
Interventions: Drug: ponatinib; Drug: imatinib (Gleevec/ Glivec)
Sponsors: Ariad Pharmaceuticals; Ariad Pharmaceuticals
Recruiting - verified June 2013 - Condition: Mantle Cell Lymphoma
Interventions: Drug: Rituximab; Drug: Bendamustine; Drug: Cytarabine
Sponsors: Dana-Farber Cancer Institute; Dana-Farber Cancer Institute; Massachusetts General Hospital
Recruiting - verified May 2013 - Condition: Carcinoma, Non-Small-Cell Lung
Intervention: Drug: Dose escalation followed by treatment with MTD
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified June 2013 - Conditions: Adult Anaplastic Astrocytoma; Adult Anaplastic Oligodendroglioma; Adult Diffuse Astrocytoma; Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Adult Oligodendroglioma; Recurrent Adult Brain Tumor
Interventions: Biological: anti-endoglin monoclonal antibody TRC105; Biological: bevacizumab; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified June 2013 - Condition: Psoriasis
Interventions: Drug: 80 mg ixekizumab; Drug: 50 mg etanercept; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified June 2013 - Condition: Cystic Fibrosis
Interventions: Drug: Aztreonam for Inhalation Solution (AZLI); Drug: Placebo
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified July 2012 - Condition: Anorexia Nervosa
Interventions: Drug: RM-131; Drug: Placebo
Sponsors: Rhythm Pharmaceuticals, Inc.; Rhythm Pharmaceuticals, Inc.
Recruiting - verified May 2013 - Condition: Gastroesophageal Reflux Disease
Intervention: Drug: Dexlansoprazole
Sponsors: Takeda; Takeda
Recruiting - verified June 2013 - Condition: Rheumatoid Arthritis
Intervention: Drug: Secukinumab
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified June 2013 - Conditions: Gastroesophageal Reflux Disease; Erosive Esophagitis
Interventions: Drug: Dexlansoprazole; Drug: Dexlansoprazole; Drug: Placebo
Sponsors: Takeda; Takeda
Recruiting - verified June 2013 - Condition: Parkinson's Disease
Interventions: Behavioral: Structured exercise; Behavioral: Lifestyle exercise
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs
Recruiting - verified June 2013 - Conditions: Breast Cancer; HER-2 Positive Breast Cancer; Triple Negative Breast Cancer
Intervention: Drug: ganetespib
Sponsors: Synta Pharmaceuticals Corp.; Synta Pharmaceuticals Corp.
Recruiting - verified May 2013 - Conditions: Uncontrolled Hypertension; Atrial Fibrillation
Intervention: Device: Renal sympathetic denervation
Sponsors: Mount Sinai School of Medicine; Vivek Reddy
Recruiting - verified May 2013 - Condition: Relapsing-remitting Multiple Sclerosis (RRMS)
Interventions: Drug: fingolimod; Drug: copaxone
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified June 2013 - Condition: Parkinson's Disease
Intervention:
Sponsors: National Parkinson Foundation; National Parkinson Foundation
Recruiting - verified May 2013 - Condition: Behavioral Variant Frontotemporal Dementia (bvFTD)
Interventions: Drug: TRx0237; Drug: Placebo
Sponsors: TauRx Therapeutics Ltd; TauRx Therapeutics Ltd
Recruiting - verified May 2013 - Conditions: HER2-positive Breast Cancer; Male Breast Cancer; Recurrent Breast Cancer; Stage IV Breast Cancer; Tumors Metastatic to Brain
Interventions: Drug: lapatinib ditosylate; Radiation: whole-brain radiation therapy
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified March 2013 - Condition: Sinusitis
Intervention: Device: SinuSys Dilation System
Sponsors: SinuSys Corporation; SinuSys Corporation
Recruiting - verified June 2013 - Condition: Idiopathic Pulmonary Fibrosis
Interventions: Biological: Tralokinumab; Biological: Tralokinumab; Other: Placebo
Sponsors: MedImmune LLC; MedImmune LLC
Recruiting - verified May 2013 - Condition: Complex Regional Pain Syndrome I (CRPS I)
Intervention: Drug: Gabapentin
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital
Recruiting - verified May 2013 - Conditions: Alcohol Dependence; Alcohol Abuse; Alcohol Use Disorders; Alcoholism
Interventions: Drug: ABT-436; Drug: Matched Placebo - Sugar Pill
Sponsors: National Institute on Alcohol Abuse and Alcoholism (NIAAA); National Institute on Alcohol Abuse and Alcoholism (NIAAA); AbbVie
Recruiting - verified May 2013 - Conditions: Asthma; Allergies
Interventions: Biological: Allergen Challenge; Procedure: PET-CT imaging(13NN perfusion/ventilation, 18FDG inflammation, and CT imaging)
Sponsors: Massachusetts General Hospital; Andrew D. Luster, M.D.,Ph.D.; National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified June 2013 - Condition: Cytomegalovirus Infections
Intervention: Drug: Maribavir
Sponsors: ViroPharma; ViroPharma
Recruiting - verified June 2013 - Condition: Herpes Zoster (HZ)
Interventions: Biological: Herpes Zoster vaccine GSK1437173A; Biological: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified June 2013 - Condition: Breast Cancer
Interventions: Drug: Paclitaxel + LCL161; Drug: paclitaxel
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified June 2013 - Condition: Melanoma
Interventions: Drug: Vemurafenib; Drug: Leflunomide
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital
Recruiting - verified November 2012 - Condition: Emphysema
Intervention: Device: PneumRx RePneu Lung Volume Reduction Coil (RePneu LVRC) System
Sponsors: PneumRx, Inc.; PneumRx, Inc.
Recruiting - verified December 2012 - Condition: Metastatic Pancreatic Cancer
Interventions: Drug: nab-paclitaxel; Drug: gemcitabine; Drug: placebo; Drug: M402
Sponsors: Momenta Pharmaceuticals, Inc.; Momenta Pharmaceuticals, Inc.
Recruiting - verified June 2013 - Condition: Acute Kidney Injury
Interventions: Biological: AC607; Biological: Vehicle Only
Sponsors: AlloCure Inc.; AlloCure Inc.
Recruiting - verified June 2013 - Conditions: Childhood Central Nervous System Choriocarcinoma; Childhood Central Nervous System Embryonal Tumor; Childhood Central Nervous System Germ Cell Tumor; Childhood Central Nervous System Germinoma; Childhood Central Nervous System Mixed Germ Cell Tumor; Childhood Central Nervous System Teratoma; Childhood Central Nervous System Yolk Sac Tumor; Childhood Pineal Parenchymal Tumor
Interventions: Procedure: therapeutic conventional surgery; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy; Drug: carboplatin; Drug: etoposide; Drug: ifosfamide
Sponsors: Children's Oncology Group; Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified June 2013 - Condition: Multiple Myeloma
Interventions: Drug: Placebo; Drug: Dexamethasone; Drug: Bortezomib; Biological: Tabalumab
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified June 2013 - Conditions: Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
Interventions: Drug: Ibrutinib; Drug: Bendamustine hydrochloride; Drug: Rituximab; Drug: Placebo
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC; Pharmacyclics
Recruiting - verified June 2013 - Conditions: Surgery; Anaesthesia; Ventilator-Induced Lung Injury; Lung Injury; Pneumonia; Pneumothorax; Respiratory Distress Syndrome, Adult; Respiratory Insufficiency
Intervention:
Sponsors: European Society of Anaesthesiology; European Society of Anaesthesiology; Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Recruiting - verified May 2013 - Condition: Breast Cancer
Interventions: Drug: BKM120 Matching placebo; Drug: Fulvestrant; Drug: BKM120
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2013 - Condition: Healthy
Intervention: Drug: isoquercetin or quercetin
Sponsors: Dana-Farber Cancer Institute; Beth Israel Deaconess Medical Center
Recruiting - verified May 2013 - Conditions: Non-Hodgkin's Lymphoma; Hodgkin Lymphoma; Multiple Myeloma; Chronic Myelogenous Leukemia
Intervention: Biological: Nivolumab
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified May 2013 - Condition: Advanced HER2-positive Breast Cancer or Gastric Cancer
Interventions: Drug: LJM716; Drug: Trastuzumab
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified June 2013 - Condition: Sarcoma
Interventions: Drug: RO5045337; Drug: doxorubicin
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified June 2013 - Condition: Distal Radius Fracture
Interventions: Procedure: Open Reduction and Internal Fixation; Procedure: External Fixation; Procedure: Percutaneous Pinning; Procedure: Closed Reduction and casting
Sponsors: University of Michigan; University of Michigan; National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); National Institute on Aging (NIA)
Recruiting - verified May 2013 - Condition: Neoplasms, Hematologic
Intervention: Drug: 120 mg LY2784544
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified June 2013 - Condition: ALK-Rearranged Non-Small Cell Lung Cancer
Interventions: Drug: CH5424802; Drug: CH5424802
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche; Chugai Pharmaceutical
Recruiting - verified June 2013 - Condition: Solid Tumors
Interventions: Drug: Iniparib (SAR240550/BSI-201); Drug: Carboplatin; Drug: Doxorubicin HCL liposome injection; Drug: Gemcitabine; Drug: Irinotecan; Drug: Paclitaxel; Drug: Topotecan
Sponsors: Sanofi; Sanofi
Recruiting - verified June 2013 - Condition: Melanoma
Interventions: Drug: dabrafenib plus trametinib; Drug: dabrafenib plus trametinib placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2013 - Conditions: Adenocarcinoma of the Pancreas; BRCA1 Mutation Carrier; BRCA2 Mutation Carrier; Recurrent Pancreatic Cancer; Stage III Pancreatic Cancer; Stage IV Pancreatic Cancer
Interventions: Drug: veliparib; Drug: gemcitabine hydrochloride; Drug: cisplatin
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013 - Condition: Multiple Myeloma
Intervention: Drug: Cabozantinib
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital
Recruiting - verified June 2013 - Conditions: Advanced Renal Cell Carcinoma; Renal Cell Carcinoma; Metastatic Renal Cell Carcinoma
Interventions: Drug: Standard Treatment; Biological: AGS-003
Sponsors: Argos Therapeutics; Argos Therapeutics
Recruiting - verified June 2013 - Condition: Prostate Cancer
Interventions: Drug: Cabozantinib; Drug: Abiraterone
Sponsors: Dana-Farber Cancer Institute; Dana-Farber Cancer Institute
Recruiting - verified June 2013 - Condition: Prostate Cancer
Interventions: Drug: cabazitaxel, prednisone, custirsen sodium; Drug: cabazitaxel, prednisone
Sponsors: OncoGenex Technologies; OncoGenex Technologies; Teva Pharmaceutical Industries
Recruiting - verified May 2013 - Conditions: Carcinoid Tumor of the Small Bowel; Neuroendocrine Tumour
Interventions: Drug: Octreotide; Drug: Octreotide; Drug: 177Lu-DOTA0-Tyr3-Octreotate
Sponsors: Advanced Accelerator Applications; Advanced Accelerator Applications; Pierrel Research Europe GmbH
Recruiting - verified June 2013 - Condition: Huntington's Disease
Intervention:
Sponsors: CHDI Foundation, Inc.; CHDI Foundation, Inc.
Recruiting - verified May 2013 - Condition: Acute Lymphoblastic Leukemia
Interventions: Drug: inotuzumab ozogamicin; Drug: FLAG (fludarabine, cytarabine and G-CSF); Drug: HIDAC (high dose cytarabine); Drug: cytarabine and mitoxantrone
Sponsors: Pfizer; Pfizer; Union Chimique Belge
Recruiting - verified June 2013 - Conditions: Relapsed Multiple Myeloma; Refractory Multiple Myeloma
Interventions: Drug: MLN9708 + Lenalidomide + Dexamethasone; Drug: Placebo + Lenalidomide + Dexamethasone
Sponsors: Millennium Pharmaceuticals, Inc.; Millennium Pharmaceuticals, Inc.
Recruiting - verified June 2013 - Condition: Neoplasms
Interventions: Drug: GDC-0973; Drug: GDC-0068
Sponsors: Genentech; Genentech
Recruiting - verified May 2013 - Condition: Celiac Disease
Intervention:
Sponsors: Alvine Pharmaceuticals Inc.; Alvine Pharmaceuticals Inc.
Recruiting - verified May 2013 - Conditions: Chronic Lymphocytic Leukemia; Lymphoma; Multiple Myeloma
Intervention: Drug: Plerixafor
Sponsors: Tufts Medical Center; Tufts Medical Center
Not yet recruiting - verified May 2013 - Condition: Cardiomegaly
Intervention: Drug: MEK162
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2013 - Conditions: Neurofibromatosis Type 1; Recurrent Childhood Pilocytic Astrocytoma; Recurrent Childhood Visual Pathway Glioma
Intervention: Drug: lenalidomide
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified June 2013 - Condition: Lung Cancer
Interventions: Drug: Afatinib; Radiation: Radiation; Drug: Cisplatin; Drug: Pemetrexed; Procedure: Surgery
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital
Recruiting - verified June 2013 - An Open-Label, Long-Term Study of Oral Treprostinil in Subjects With Pulmonary Arterial HypertensionCondition: Pulmonary Arterial Hypertension
Intervention: Drug: UT-15C (treprostinil diethanolamine)
Sponsors: United Therapeutics; United Therapeutics
Not yet recruiting - verified June 2013 - Condition: Pulmonary Arterial Hypertension
Interventions: Drug: UT-15C (treprostinil diethanolamine); Drug: Placebo
Sponsors: United Therapeutics; United Therapeutics
Recruiting - verified June 2013 - Conditions: Parkinson's Disease; Primary Parkinsonism; Lewy Body Parkinson's Disease
Intervention: Drug: 18F-AV-133
Sponsors: Avid Radiopharmaceuticals; Avid Radiopharmaceuticals
Recruiting - verified June 2013 - Condition: Acute Myeloid Leukemia
Interventions: Drug: PF-04449913; Drug: Low dose ARA-C (LDAC); Drug: PF-04449913; Drug: Decitabine; Drug: PF-04449913; Drug: Daunorubicin; Drug: Cytarabine; Drug: Pf-04449913; Drug: Daunorubicin; Drug: Cytarabine; Drug: PF-04449913; Drug: Low dose ARA-C (LDAC)
Sponsors: Pfizer; Pfizer
Recruiting - verified June 2013 - Condition: Magnetic Resonance Imaging
Intervention: Drug: Gadobutrol (Gadavist, BAY86-4875)
Sponsors: Bayer; Bayer
Recruiting - verified May 2013 - Condition: Irritable Bowel Syndrome With Diarrhea
Interventions: Drug: rifaximin; Drug: placebo
Sponsors: Salix Pharmaceuticals; Salix Pharmaceuticals
Recruiting - verified January 2013 - Condition: Colorectal Neoplasms
Intervention: Drug: Regorafenib (BAY73-4506)
Sponsors: Bayer; Bayer
Available - verified June 2013 - Condition: Cornea Tissue Preservation Time
Intervention: Biological: Cornea tissue transplant
Sponsors: Case Western Reserve University; Case Western Reserve University; National Eye Institute (NEI); Jaeb Center for Health Research
Recruiting - verified May 2013 - Conditions: Cardiac Surgery; Erythrocyte Transfusion
Intervention:
Sponsors: New England Research Institutes; New England Research Institutes; National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified May 2013 - Conditions: Esophageal Deviation; Atrial Fibrillation; Ablation
Intervention: Procedure: esophageal deviation
Sponsors: Mount Sinai School of Medicine; Vivek Reddy; Boston Scientific Corporation
Recruiting - verified May 2013 - Condition: Sclerosis, Systemic
Interventions: Drug: tocilizumab [RoActemra/Actemra]; Drug: Placebo; Drug: tocilizumab [RoActemra/Actemra]
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified June 2013 - Condition: Schizophrenia
Interventions: Drug: PP3M 175 mg eq.; Drug: PP3M 263 mg eq.; Drug: PP3M 350 mg eq.; Drug: PP3M 525 mg eq.; Drug: Placebo (20% Intralipid emulsion)
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified June 2013 - Condition: Severe Aortic Stenosis
Intervention: Device: Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI)
Sponsors: Medtronic Cardiovascular; Medtronic Cardiovascular
Recruiting - verified May 2013 - Condition: Solid Tumors Harboring a BRAF V600 Mutation
Interventions: Drug: LGX818; Drug: MEK162
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified June 2013 - Condition: Inflammation
Interventions: Other: Avenanthramide-enriched oats; Other: Refined flour absent avenanthramides
Sponsors: Tufts University; Tufts University; Agriculture and Agri-Food Canada
Recruiting - verified May 2013 - Conditions: Obesity; Aging
Intervention: Other: Calorie Restriction
Sponsors: Tufts University; Tufts University
Recruiting - verified June 2013 - Condition: Schizophrenia
Interventions: Drug: eszopiclone; Drug: placebo
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; Beth Israel Deaconess Medical Center; Mclean Hospital
Recruiting - verified May 2013 - Condition: Prostatic Neoplasms
Intervention: Drug: Radium-223 dichloride (BAY88-8223)
Sponsors: Bayer; Bayer
Available - verified June 2013 - Conditions: Preeclampsia; Pregnancy Induced Hypertension
Intervention: Drug: Irbesartan
Sponsors: Brigham and Women's Hospital; Brigham and Women's Hospital
Recruiting - verified May 2013 - Conditions: Metastatic Castration-resistant Prostate Cancer; Metastatic Breast Cancer
Interventions: Drug: Abiraterone acetate; Drug: Abiraterone acetate
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified May 2013 - Condition: Schizophrenia
Interventions: Drug: PP3M 175 mg eq.; Drug: PP3M 263 mg eq.; Drug: PP3M 350 mg eq.; Drug: PP3M 525 mg eq.; Drug: Placebo (20% Intralipid); Drug: PP1M 50 mg eq.; Drug: PP1M 75 mg eq.; Drug: PP1M 100 mg eq.; Drug: PP1M 150 mg eq.
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified June 2013 - Condition: Non-small-cell Lung Cancer
Interventions: Radiation: SBRT (stereotactic body radiotherapy); Radiation: SBPT (stereotactic body proton therapy)
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; National Institutes of Health (NIH)
Recruiting - verified June 2013 - Condition: Pelvic Organ Prolapse
Interventions: Other: Mechanical Bowel Prep; Other: No Mechanical Bowel Prep
Sponsors: Boston Urogynecology Associates; Boston Urogynecology Associates
Recruiting - verified June 2013 - Condition: HIV Infections
Intervention: Drug: Etravirine (ETR)
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified June 2013 - Condition: HIV Infection
Interventions: Drug: Maraviroc; Drug: Emtricitabine; Drug: Tenofovir disoproxil fumarate; Other: Maraviroc placebo; Other: Emtricitabine placebo; Other: Tenofovir disoproxil fumarate placebo
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID); HIV Prevention Trials Network
Recruiting - verified June 2013 - Condition: Pulmonary Arterial Hypertension
Interventions: Device: St Jude Medical C7 Dragonfly Optical Coherence Tomography (OCT); Device: Boston Scientific Intravascular Ultrasound
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; Actelion
Recruiting - verified May 2013 - Conditions: Childhood Hepatocellular Carcinoma; Papillary Thyroid Cancer; Previously Treated Childhood Rhabdomyosarcoma; Recurrent Childhood Liver Cancer; Recurrent Childhood Rhabdomyosarcoma; Recurrent Thyroid Cancer; Recurrent Wilms Tumor and Other Childhood Kidney Tumors
Interventions: Drug: sorafenib tosylate; Other: pharmacological study; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified June 2013 - Condition: Non-Small Cell Lung Cancer
Interventions: Drug: onartuzumab; Drug: Placebo; Drug: paclitaxel; Drug: cisplatin/carboplatin
Sponsors: Genentech; Genentech
Recruiting - verified May 2013 - Condition: Diffuse Large B-Cell Lymphoma
Intervention: Drug: Fostamatinib
Sponsors: AstraZeneca; AstraZeneca
Recruiting - verified June 2013 - Conditions: Amyotrophic Lateral Sclerosis; Nervous System Diseases; Sclerosis; Motor Neuron Disease; Spinal Cord Diseases; Central Nervous System Diseases; Neurodegenerative Diseases; Neuromuscular Diseases; ALS
Intervention:
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; ALS Therapy Alliance
Recruiting - verified June 2013 - Condition: Alzheimer's Disease
Interventions: Drug: BMS-241027; Drug: BMS-241027; Drug: BMS-241027; Drug: Placebo matching BMS-241027
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified May 2013 - Conditions: HIV Infections; Hepatitis C
Interventions: Drug: Pegylated-Interferon Alfa 2b (PEG-IFN); Drug: Ribavirin (RBV); Drug: Boceprevir (BOC)
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified June 2013 - Conditions: Abdominal Obesity; Insulin Resistance; Hypertriglyceridemia
Interventions: Drug: Acipimox; Drug: Placebo
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; American Diabetes Association
Recruiting - verified May 2013 - Condition: Epilepsy
Intervention: Drug: Lacosamide
Sponsors: UCB, Inc.; UCB, Inc.
Recruiting - verified May 2013 - Conditions: Congenital Bleeding Disorder; Haemophilia A
Intervention: Drug: NNC 0129-0000-1003
Sponsors: Novo Nordisk; Novo Nordisk
Recruiting - verified June 2013 - Condition: HER2 Negative Breast Cancer
Interventions: Biological: NeuVax vaccine; Biological: Leukine (sargramostim, GM-CSF) and water for injection
Sponsors: Galena Biopharma, Inc.; Galena Biopharma, Inc.
Recruiting - verified June 2013 - Condition: Breast Cancer
Interventions: Drug: Veliparib; Radiation: Standard radiation treatment
Sponsors: University of Michigan Cancer Center; University of Michigan Cancer Center
Recruiting - verified June 2013 - Conditions: Hypercholesterolemia; Coronary Heart Disease
Interventions: Drug: mipomersen sodium 200 mg; Drug: Placebo; Drug: mipomersen sodium 70 mg
Sponsors: Genzyme; Genzyme
Recruiting - verified June 2013 - Condition: Colorectal Cancer
Interventions: Drug: GS-6624; Drug: FOLFIRI; Drug: GS-6624; Drug: FOLFIRI; Drug: GS-6624; Drug: FOLFIRI; Drug: Placebo; Drug: FOLFIRI
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified May 2013 - Condition: Breast Cancer
Intervention:
Sponsors: Dana-Farber Cancer Institute; Dana-Farber Cancer Institute
Recruiting - verified June 2013 - Condition: Hepatitis C
Intervention:
Sponsors: University of North Carolina, Chapel Hill; University of North Carolina, Chapel Hill; University of Florida
Recruiting - verified June 2013 - Condition: HIV Infections
Interventions: Biological: Quadrivalent HPV Vaccine; Biological: Placebo Vaccine for Male Participants Only; Biological: Placebo Vaccine for Female Participants Only
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified June 2013 - Conditions: Systemic Sclerosis; Ulcers
Interventions: Drug: macitentan 3mg; Drug: macitentan 10mg; Drug: placebo
Sponsors: Actelion; Actelion
Recruiting - verified June 2013 - Conditions: Acute Lymphoid Leukemia; Acute Myeloid Leukemia; Chronic Lymphocytic Leukemia; Multiple Myeloma; Solid Tumors
Interventions: Drug: brentuximab vedotin; Drug: brentuximab vedotin
Sponsors: Seattle Genetics, Inc.; Seattle Genetics, Inc.
Recruiting - verified May 2013 - Condition: Squamous Cell Carcinoma of the Head and Neck
Intervention: Biological: Dalantercept
Sponsors: Acceleron Pharma, Inc.; Acceleron Pharma, Inc.
Recruiting - verified May 2013 - Conditions: Pulmonary Arterial Hypertension; Pulmonary Hypertension
Interventions: Drug: Nitric Oxide; Other: Placebo; Drug: Nitric Oxide
Sponsors: INO Therapeutics; INO Therapeutics
Recruiting - verified May 2013 - Condition: Smoking Cessation
Interventions: Drug: Placebo; Drug: varenicline tartrate; Drug: bupropion hydrochloride; Drug: Nicotine Replacement Therapy Patch
Sponsors: Pfizer; Pfizer; GlaxoSmithKline
Recruiting - verified May 2013 - Condition: Pulmonary Emphysema
Interventions: Device: Treatment plus Optimal Medical Therapy; Other: Optimal Medical Therapy
Sponsors: Aeris Therapeutics; Aeris Therapeutics
Recruiting - verified June 2013 - Condition: Breast Cancer
Intervention: Drug: Cabozantinib and fulvestrant
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; Exelixis
Recruiting - verified June 2013 - Condition: Smoldering Multiple Myeloma
Intervention: Biological: Elotuzumab (BMS-901608; HuLuc63)
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; AbbVie
Recruiting - verified May 2013 - Condition: Cancer
Intervention: Drug: Metformin
Sponsors: Tufts Medical Center; Tufts Medical Center
Recruiting - verified June 2013 - Condition: Colon Cancer
Intervention: Drug: Metformin
Sponsors: Tufts Medical Center; Tufts Medical Center
Recruiting - verified June 2013 - Conditions: Prostate Cancer; Psychosocial Effects of Cancer and Its Treatment; Radiation Toxicity; Sexual Dysfunction
Intervention: Radiation: hypofractionated radiation therapy
Sponsors: Radiation Therapy Oncology Group; Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified June 2013 - Conditions: Keratoconus; Corneal Ectasia
Interventions: Device: KXL System (15 mW/cm2); Device: KXL System (30 mW/cm2); Device: KXL System (45 mW/cm2); Drug: riboflavin ophthalmic solution
Sponsors: ACOS; ACOS
Recruiting - verified June 2013 - Condition: Breast Cancer
Interventions: Drug: fulvestrant; Drug: GDC-0941; Drug: GDC-0980; Drug: placebo; Drug: GDC-0941; Drug: placebo
Sponsors: Genentech; Genentech
Recruiting - verified June 2013 - Condition: Fibromyalgia
Interventions: Drug: Pregabalin; Drug: placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013 - Condition: Breast Cancer
Interventions: Device: AeroForm Tissue Expansion; Procedure: Saline Tissue Expansion
Sponsors: AirXpanders, Inc.; AirXpanders, Inc.
Recruiting - verified June 2013 - Condition: Hepatorenal Syndrome
Interventions: Drug: 5mg Ifetroban Injection; Drug: 15mg Ifetroban Injection; Drug: 50mg Ifetroban Injection; Drug: 150mg Ifetroban Injection; Other: 5% Dextrose in Water
Sponsors: Cumberland Pharmaceuticals; Cumberland Pharmaceuticals
Recruiting - verified June 2013 - Condition: Non-24-Hour Sleep-Wake Disorder
Intervention: Drug: tasimelteon
Sponsors: Vanda Pharmaceuticals; Vanda Pharmaceuticals
Recruiting - verified May 2013 - Condition: Endometrial Neoplasms
Interventions: Drug: PF-05212384; Drug: PF-05212384; Drug: PF-05212384
Sponsors: Pfizer; Pfizer
Recruiting - verified June 2013 - Conditions: Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell
Interventions: Drug: brentuximab vedotin; Drug: rituximab
Sponsors: Seattle Genetics, Inc.; Seattle Genetics, Inc.
Recruiting - verified May 2013 - Condition: Glioblastoma
Interventions: Drug: BKM120 + temozolomide; Drug: BKM120 +temozolomide with/without radiotherapy
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified June 2013 - Conditions: Ejaculatory Dysfunction; Hypogonadism
Interventions: Drug: Testosterone Solution 2%; Drug: Placebo Solution
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified June 2013 - Conditions: Non-Hodgkin's Lymphoma; Hodgkin's Lymphoma; Multiple Myeloma; Chronic Lymphocytic Leukemia; Acute Myelogenous Leukemia
Interventions: Drug: Fludarabine; Drug: Melphalan; Radiation: Total Body Radiation; Biological: Cord Blood
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital
Recruiting - verified May 2013 - Conditions: Tuberculosis; HIV Infections
Interventions: Drug: Rifapentine (RPT); Drug: Isoniazid (INH); Dietary Supplement: Pyridoxine (Vitamin B6)
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2013 - Conditions: Tumors; Medical Oncology; Neoplasms
Interventions: Drug: AGS-22M6E; Drug: ASG-22CE
Sponsors: Astellas Pharma Inc; Astellas Pharma Inc; Agensys, Inc.; Seattle Genetics, Inc.
Recruiting - verified June 2013 - Conditions: Alzheimer Disease; Mild Cognitive Impairment; Neurodegenerative Diseases
Intervention: Drug: Florbetapir F 18
Sponsors: Avid Radiopharmaceuticals; Avid Radiopharmaceuticals
Recruiting - verified June 2013 - Condition: Gastrointestinal Stromal Tumors
Interventions: Drug: sunitinib malate dose escalation; Drug: sunitinib malate
Sponsors: Pfizer; Pfizer
Recruiting - verified June 2013 - Conditions: Sickle Cell Disease; Pain
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Nursing Research (NINR)
Recruiting - verified April 2012 - Conditions: Cachexia; Non-Small Cell Lung Cancer
Interventions: Drug: Anamorelin HCl; Drug: Placebo
Sponsors: Helsinn Therapeutics (U.S.), Inc; Helsinn Therapeutics (U.S.), Inc
Recruiting - verified June 2013 - Conditions: Cachexia; Non-Small Cell Lung Cancer
Interventions: Drug: Anamorelin HCl; Drug: Placebo
Sponsors: Helsinn Therapeutics (U.S.), Inc; Helsinn Therapeutics (U.S.), Inc
Recruiting - verified June 2013 - Conditions: Chronic Pain; Osteoarthritis
Intervention: Device: Transcranial Direct Current Stimulation
Sponsors: Spaulding Rehabilitation Hospital; Spaulding Rehabilitation Hospital; Highland Instruments, Inc.
Recruiting - verified May 2013 - Condition: Acute Myeloid Leukemia
Intervention:
Sponsors: Center for International Blood and Marrow Transplant Research; Center for International Blood and Marrow Transplant Research; Resource for Clinical Investigations in Blood and Marrow Transplantation (RCI-BMT); Pediatric Blood and Marrow Transplant Consortium; St. Baldrick's Foundation; Otsuka Pharmaceutical Development & Commercialization, Inc.
Recruiting - verified June 2013 - Conditions: Brain and Central Nervous System Tumors; Cognitive/Functional Effects; Fatigue; Neurotoxicity; Psychosocial Effects of Cancer and Its Treatment
Interventions: Drug: modafinil; Other: placebo
Sponsors: University of South Florida; University of South Florida; National Cancer Institute (NCI)
Recruiting - verified September 2011 - Conditions: Femoral Neck Fractures; Intertrochanteric Fracture
Interventions: Procedure: Gamma3 Intramedullary Nails (Stryker); Procedure: Sliding Hip Screws
Sponsors: Stryker Trauma GmbH; Stryker Trauma GmbH; Stryker Osteosynthesis; Global Research Solutions
Recruiting - verified May 2013 - Condition: Prevention of GvHD in Patients With Hematological Malignancies Undergoing AHSCT
Intervention: Drug: RGI-2001
Sponsors: Regimmune Inc.; Regimmune Inc.; Pacific-Link Regulatory Consulting LLC
Recruiting - verified June 2013 - Conditions: Crohn's Disease; Colitis; IBD; Inflammatory Bowel Disease
Interventions: Drug: Placebo; Drug: Ustekinumab; Drug: Ustekinumab; Drug: Ustekinumab; Drug: Ustekinumab
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified June 2013 - Conditions: Crohn's Disease; Inflammatory Bowel Disease; IBD; Colitis
Interventions: Drug: Group 3: ustekinumab approximately 6 mg/kg; Drug: Group 1: Placebo; Drug: Group 2 ustekinumab 130 mg
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified June 2013 - Conditions: Acute Ischemic Stroke; Diabetes; Hyperglycemia
Interventions: Drug: IV insulin to maintain target glucose concentration of 80-130 mg/dL; Drug: Standard Care control - sliding scale insulin to keep glucose less than 180 mg/dL
Sponsors: University of Virginia; University of Virginia; Neurological Emergencies Treatment Trials Network (NETT); Medical University of South Carolina; Medical Automation Systems, an Alere Company; National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified June 2013 - Condition: Hematologic Neoplasms
Intervention:
Sponsors: Center for International Blood and Marrow Transplant Research; Center for International Blood and Marrow Transplant Research; National Marrow Donor Program
Recruiting - verified May 2013 - Condition: Renal Cell Carcinoma
Interventions: Drug: BMS-936558 (Anti-PD-1); Drug: BMS-936558 (Anti-PD-1); Drug: BMS-936558 (Anti-PD-1)
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Ono Pharma USA Inc
Recruiting - verified May 2013 - Condition: Acute Lymphocytic Leukemia
Intervention: Drug: Inotuzumab Ozogamicin
Sponsors: Pfizer; Pfizer; UCB, Inc.
Recruiting - verified May 2013 - Condition: Rheumatoid Arthritis
Interventions: Drug: Secukinumab (75 mg); Drug: Secukinumab (150 mg); Drug: Placebo; Drug: Abatacept
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified June 2013 - Condition: Non-Small Cell Lung Cancer
Interventions: Drug: bevacizumab [Avastin]; Drug: Standard of care treatment
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified June 2013 - Conditions: Melanoma; Breast Neoplasms; Lobular Carcinoma; Triple-negative Breast Cancer; Pancreatic Adenocarcinoma
Intervention: Drug: LGK974
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2013 - Condition: Head and Neck Neoplasms
Interventions: Drug: Placebo; Drug: Afatinib
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified June 2013 - Conditions: SCID; ADA-SCID; XSCID; Leaky SCID; Omenn Syndrome; Reticular Dysgenesis
Intervention:
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID); Office of Rare Diseases (ORD)
Recruiting - verified May 2013 - Conditions: Brain and Central Nervous System Tumors; Nausea and Vomiting; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Procedure: Real Acupressure Band; Procedure: Placebo Acupressure Band
Sponsors: University of South Florida; University of South Florida; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Head and Neck Neoplasms; Carcinoma, Squamous Cell
Interventions: Drug: Afatinib; Drug: Methotrexate
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified June 2013 - Condition: Sarcoma
Interventions: Procedure: therapeutic conventional surgery; Radiation: 3-dimensional conformal radiation therapy
Sponsors: European Organisation for Research and Treatment of Cancer - EORTC; European Organisation for Research and Treatment of Cancer - EORTC
Recruiting - verified June 2013 - Condition: Atrophy, Geographic
Interventions: Drug: GSK933776; Drug: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2013 - Condition: Hypertension, Pulmonary
Intervention: Drug: Ambrisentan
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2013 - Condition: Advanced Liposarcoma or Leiomyosarcoma
Interventions: Drug: Trabectedin; Drug: Dacarbazine
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC; Pharma Mar, S.A.U.
Recruiting - verified June 2013 - Condition: Coronary Artery Disease
Intervention: Drug: Flurpiridaz F18
Sponsors: Lantheus Medical Imaging; Lantheus Medical Imaging
Recruiting - verified February 2013 - Condition: Melanoma and Metastatic Colorectal Cancer
Intervention: Drug: LGX818
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2013 - Condition: Hepatocellular Carcinoma
Interventions: Device: HepaSphere/QuadraSphere Microspheres; Procedure: PVA, lipiodol, doxorubicin
Sponsors: Merit Medical Systems, Inc.; Merit Medical Systems, Inc.
Recruiting - verified March 2013 - Conditions: High Grade Glioma: Glioblastoma (GBM); High Grade Glioma: Gliosarcoma; Anaplastic Astrocytoma (AA); Anaplastic Oligodendroglioma (AO); Mixed Anaplastic Oligoastrocytoma (AOA)
Interventions: Drug: Plerixafor; Drug: Plerixafor; Drug: Bevacizumab; Drug: Plerixafor; Procedure: Surgery
Sponsors: Dana-Farber Cancer Institute; Patrick Y. Wen, MD; Dana-Farber Cancer Institute; Brigham and Women's Hospital; Massachusetts General Hospital; Genzyme
Recruiting - verified June 2013 - Condition: Carotid Stenosis
Intervention: Drug: Gadobutrol (Gadovist, BAY86-4875)
Sponsors: Bayer; Bayer
Recruiting - verified May 2013 - Conditions: Chronic Lymphocytic Leukemia; Non-Hodgkin Lymphoma
Intervention: Drug: ABT-199
Sponsors: AbbVie; AbbVie (prior sponsor, Abbott); Genentech
Recruiting - verified May 2013 - Condition: Prostate Cancer Metastatic
Interventions: Biological: PROSTVAC-V; Biological: PROSTVAC-F; Drug: GM-CSF; Other: GM-CSF Placebo; Biological: Placebo
Sponsors: BN ImmunoTherapeutics; BN ImmunoTherapeutics
Recruiting - verified February 2013 - Condition: Hypertension, Pulmonary
Interventions: Drug: Ambrisentan - low dose; Drug: Ambrisentan - high dose
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2013 - Condition: Symptomatic Severe Aortic Stenosis
Interventions: Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis; Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis; Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis; Device: AVR with a surgical heart valve; Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis; Device: AVR with a surgical heart valve; Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis; Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis; Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis; Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis; Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis; Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis
Sponsors: Edwards Lifesciences; Edwards Lifesciences
Recruiting - verified May 2013 - Conditions: Prostate Cancer; Prostatic Neoplasm
Intervention: Drug: abiraterone acetate in combination with prednisone
Sponsors: Janssen Biotech, Inc.; Janssen Biotech, Inc.
Recruiting - verified May 2013 - Condition: Crohn's Disease
Interventions: Drug: GSK1605786A; Drug: Placebo; Drug: GSK1605786A
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2013 - Condition: Crohn's Disease
Intervention: Drug: GSK1605786A
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified June 2013 - Condition: Bronchiolitis Obliterans
Interventions: Drug: fluticasone propionate; Drug: montelukast sodium; Procedure: pulmonary function testing; Other: questionnaire administration; Procedure: quality-of-life assessment; Other: laboratory biomarker analysis; Genetic: protein analysis; Drug: azithromycin
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified June 2013 - Conditions: Fungal Infection; Leukemia; Neutropenia
Interventions: Drug: caspofungin acetate; Drug: fluconazole
Sponsors: Children's Oncology Group; Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2013 - Condition: Breast Cancer
Intervention: Drug: rosuvastatin
Sponsors: Dana-Farber Cancer Institute; Beth Israel Deaconess Medical Center; Dana-Farber Cancer Institute; Massachusetts General Hospital; National Institutes of Health (NIH)
Recruiting - verified May 2013 - Conditions: Left Ventricular Dysfunction; Heart Failure
Interventions: Device: CardioFit® System; Other: Standard of Care
Sponsors: BioControl Medical; BioControl Medical
Recruiting - verified May 2013 - Condition: HIV Infections
Interventions: Drug: GSK1349572 tablet formulation; Drug: GSK1349572 oral pediatric granules taken as suspension or granules
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified June 2013 - Condition: Anorexia Nervosa
Interventions: Drug: RhIGF-1 with transdermal 17-beta estradiol; Drug: Placebo and transdermal 17-beta estradiol
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; The Hospital for Sick Children
Recruiting - verified June 2013 - Conditions: Solid Tumors; Relapsed/Refractory Sarcomas
Intervention: Drug: Vorinostat and Etoposide
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Merck; Phoenix Children's Hospital; Milton S. Hershey Medical Center; Johns Hopkins University; Sidney Kimmel Comprehensive Cancer Center; Children's Hospital Colorado; University of Florida; Alberta Children's Hospital; M.D. Anderson Cancer Center; Dana-Farber Cancer Institute; Children's Mercy Hospital & Clinics; All Children's Hospital; Arnold Palmer Hospital for Children/MD Anderson Cancer Center Orlando
Recruiting - verified May 2013 - Condition: Renal Cell Carcinoma
Intervention: Drug: BKM-120 Bevacizumab
Sponsors: Dana-Farber Cancer Institute; Toni Choueiri, MD; Beth Israel Deaconess Medical Center
Recruiting - verified June 2013 - Conditions: Obesity; Type 2 Diabetes; Metabolic Syndrome
Intervention:
Sponsors: Joslin Diabetes Center; Joslin Diabetes Center
Recruiting - verified May 2013 - Condition: Cardiac Allograft Vasculopathy
Interventions: Biological: Rituximab induction/conventional immunosuppression (tacrolimus, MMF, and steroid taper); Drug: Rituximab placebo/conventional immunosuppression (tacrolimus, MMF, and steroid taper)
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID); National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified June 2013 - Condition: Angelman Syndrome
Intervention: Drug: Levodopa/carbidopa
Sponsors: Children's Hospital Boston; Wen-Hann Tan; Rady Children's Hospital, San Diego; University of California, San Francisco; Baylor College of Medicine; Vanderbilt University; Greenwood Genetic Center; Children's Hospital Medical Center, Cincinnati; Angelman Syndrome Foundation; FDA Office of Orphan Products Development
Recruiting - verified May 2013 - Conditions: Estrogen Receptor-negative Breast Cancer; Estrogen Receptor-positive Breast Cancer; HER2-positive Breast Cancer; Progesterone Receptor-negative Breast Cancer; Progesterone Receptor-positive Breast Cancer; Recurrent Breast Cancer; Stage IV Breast Cancer
Interventions: Drug: Akt inhibitor MK2206; Drug: lapatinib ditosylate; Other: laboratory biomarker analysis; Other: pharmacogenomic studies; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified June 2013 - Conditions: Male Breast Cancer; Recurrent Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer
Interventions: Drug: Akt inhibitor MK2206; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013 - Conditions: Cardiac Surgery; Erythrocyte Transfusion
Intervention:
Sponsors: Duke University; Duke University; National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified June 2013 - Condition: Post Herpetic Neuralgia
Interventions: Drug: Pregabalin; Drug: placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified June 2013 - Condition: GERD
Interventions: Device: Nissen fundoplication; Drug: baclofen; Drug: Desipramine
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs
Recruiting - verified May 2013 - Condition: Pain
Interventions: Drug: Sativex®; Drug: Placebo (GA-0034)
Sponsors: GW Pharmaceuticals Ltd.; GW Pharmaceuticals Ltd.; Otsuka Pharmaceutical Development & Commercialization, Inc.
Recruiting - verified May 2011 - Condition: Systemic Lupus Erythematosus
Interventions: Drug: Placebo; Drug: Epratuzumab; Drug: Epratuzumab
Sponsors: UCB, Inc.; UCB, Inc.
Recruiting - verified May 2013 - Condition: Epilepsy
Interventions: Drug: Placebo; Drug: Brivaracetam; Drug: Brivaracetam
Sponsors: UCB, Inc.; UCB, Inc.
Recruiting - verified May 2013 - Condition: Critical Limb Ischemia
Interventions: Device: BMAC injection; Device: Placebo injection
Sponsors: Harvest Technologies; Harvest Technologies
Recruiting - verified May 2013 - Condition: Bipolar Disorder, Pediatric
Interventions: Drug: asenapine; Drug: Placebo to match asenapine; Drug: Rescue medication
Sponsors: Merck; Merck
Recruiting - verified May 2013 - Condition: Small Cell Lung Cancer
Interventions: Drug: IMGN901; Drug: Carboplatin and Etoposide
Sponsors: ImmunoGen, Inc.; ImmunoGen, Inc.
Recruiting - verified June 2013 - Condition: Colorectal Cancer
Interventions: Procedure: Colonoscopy; Procedure: FIT
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs
Recruiting - verified May 2013 - A Study of LCL161 in Combination With Weekly Paclitaxel in Adult Patients With Advanced Solid TumorsCondition: Solid Tumors
Interventions: Drug: LCL161; Drug: Paclitaxel
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified June 2013 - Conditions: Adult Supratentorial Primitive Neuroectodermal Tumor (PNET); Childhood Supratentorial Primitive Neuroectodermal Tumor; Ewing Sarcoma of Bone; Extraosseous Ewing Sarcoma; Extraosseous Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor; Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor; Peripheral Primitive Neuroectodermal Tumor of the Kidney; Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor
Interventions: Drug: vincristine sulfate; Drug: doxorubicin hydrochloride; Drug: cyclophosphamide; Drug: ifosfamide; Drug: etoposide; Drug: topotecan hydrochloride; Other: laboratory biomarker analysis
Sponsors: Children's Oncology Group; Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified June 2013 - Condition: Moderate Clostridium Difficile Infection
Interventions: Drug: LFF571; Drug: Vancomycin (POC)
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified June 2013 - Condition: Polycystic Kidney, Autosomal Dominant
Interventions: Drug: Bosutinib; Drug: Bosutinib; Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified June 2013 - Condition: Influenza, Human
Interventions: Drug: 300mg intravenous (IV) zanamivir and oral oseltamivir placebo; Drug: 600mg intravenous (IV) zanamivir and oral oseltamivir placebo; Drug: 75mg oral oseltamivir and intravenous zanamivir placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified June 2013 - Condition: Influenza
Interventions: Drug: Amantadine, Ribavirin, Oseltamivir; Drug: Oseltamivir
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2013 - Condition: Cancer
Interventions: Drug: pazopanib; Drug: placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2013 - Conditions: Prostate Neoplasms; Genital Neoplasms, Male; Urogenital Neoplasms; Genital Diseases, Male
Intervention: Drug: Abiraterone Acetate
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified May 2013 - Condition: Ischemic Stroke
Interventions: Drug: PF-03049423; Drug: PF-03049423; Drug: PF-03049423; Other: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified June 2013 - Condition: Leukemia
Interventions: Drug: cyclophosphamide; Drug: cytarabine; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: pegaspargase; Drug: thioguanine; Drug: vincristine sulfate
Sponsors: Children's Oncology Group; Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified June 2013 - Conditions: Degenerative and Traumatic Pathology of the Knee; Degenerative and Traumatic Pathology of the Shoulder and Elbow; Degenerative and Traumatic Pathology of the Foot and Ankle; Degenerative and Traumatic Pathology of the Hand and Wrist; Degenerative and Traumatic Pathology of the Hip
Intervention:
Sponsors: Arthrex, Inc.; Arthrex, Inc.
Recruiting - verified June 2013 - Conditions: SCID; Leaky SCID; Omenn Syndrome; Reticular Dysgenesis; ADA Deficiency; XSCID
Intervention:
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID); Office of Rare Diseases (ORD)
Recruiting - verified May 2013 - Condition: Intracerebral Hemorrhage
Intervention: Drug: Nicardipine hydrochloride
Sponsors: University of Minnesota - Clinical and Translational Science Institute; University of Minnesota - Clinical and Translational Science Institute; Medical University of South Carolina; National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified June 2013 - Conditions: Light Chain Deposition Disease; Smoldering Multiple Myeloma
Interventions: Other: clinical observation; Drug: lenalidomide; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013 - Condition: Hypertension, Pulmonary
Interventions: Drug: ambrisentan; Drug: tadalafil
Sponsors: GlaxoSmithKline; GlaxoSmithKline; Gilead Sciences
Recruiting - verified May 2013 - Condition: Psoriasis
Interventions: Drug: CP-690,550; Drug: CP-690,550
Sponsors: Pfizer; Pfizer
Recruiting - verified June 2013 - Condition: Non Squamous Lung Cancer
Interventions: Drug: treatment; Drug: treatment
Sponsors: Pfizer; Pfizer
Recruiting - verified June 2013 - Conditions: Childhood Hepatoblastoma; Previously Treated Childhood Rhabdomyosarcoma; Recurrent Childhood Acute Lymphoblastic Leukemia; Recurrent Childhood Acute Myeloid Leukemia; Recurrent Childhood Malignant Germ Cell Tumor; Recurrent Childhood Rhabdomyosarcoma; Recurrent Childhood Soft Tissue Sarcoma; Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor; Recurrent Neuroblastoma; Recurrent Osteosarcoma; Recurrent Wilms Tumor and Other Childhood Kidney Tumors
Interventions: Drug: alisertib; Other: pharmacological study; Other: laboratory biomarker analysis
Sponsors: Children's Oncology Group; Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified June 2013 - Condition: Head and Neck Squamous Cell Carcinoma
Interventions: Drug: Paclitaxel; Drug: Carboplatin; Drug: Cetuximab; Drug: Cetuximab; Drug: Docetaxel; Drug: Cisplatin; Drug: Fluorouracil; Radiation: Radiotherapy (RT); Other: Chemotherapy
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified June 2013 - Condition: Non Small Cell Lung Cancer
Interventions: Drug: COMBINED PF-02341066 AND PF-00299804; Drug: PF-00299804 FOLLOWED BY COMBINED PF-02341066 AND PF-00299804
Sponsors: Pfizer; Pfizer
Recruiting - verified June 2013 - Condition: Uveitis
Interventions: Drug: adalimumab; Drug: prednisone; Drug: prednisone; Drug: adalimumab placebo
Sponsors: AbbVie; AbbVie (prior sponsor, Abbott)
Recruiting - verified April 2013 - Condition: Uveitis
Interventions: Drug: adalimumab; Drug: prednisone; Drug: adalimumab placebo; Drug: prednisone
Sponsors: AbbVie; AbbVie (prior sponsor, Abbott)
Recruiting - verified April 2013 - Condition: Pulmonary Arterial Hypertension
Interventions: Drug: imatinib; Drug: imatinib
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified June 2013 - Conditions: Breast Cancer; Fatigue
Intervention:
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital
Recruiting - verified May 2013 - Condition: Chronic GVHD
Interventions: Drug: Sirolimus + calcineurin inhibitor + prednisone; Drug: Sirolimus + prednisone
Sponsors: Medical College of Wisconsin; Medical College of Wisconsin; National Heart, Lung, and Blood Institute (NHLBI); National Cancer Institute (NCI); Blood and Marrow Transplant Clinical Trials Network
Recruiting - verified May 2013 - Conditions: Bone Metastases; Castration-Resistant Prostate Cancer
Interventions: Drug: Alpharadin® (Radium-223 dichloride) + docetaxel; Drug: Docetaxel
Sponsors: Algeta ASA; Algeta ASA; Bayer
Recruiting - verified May 2013 - Conditions: Abscess, Intra-Abdominal; Abdominal Abscess; Abdomen, Acute; Abdominal Pain; Appendicitis; Rupture; Infection; Intestinal Perforation; Peritonitis; Ileus
Interventions: Drug: doripenem; Drug: meropenem placebo; Drug: meropenem; Drug: doripenem placebo
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified June 2013 - Condition: Complicated Urinary Tract Infections or Pyelonephritis
Interventions: Drug: doripenem; Drug: doripenem placebo; Drug: cefepime; Drug: cefepime placebo
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified May 2013 - Conditions: Childhood Infratentorial Ependymoma; Childhood Supratentorial Ependymoma; Newly Diagnosed Childhood Ependymoma
Interventions: Drug: liposomal vincristine sulfate; Other: clinical observation; Radiation: 3-dimensional conformal radiation therapy; Drug: carboplatin; Drug: cyclophosphamide; Drug: etoposide; Drug: cisplatin; Other: laboratory biomarker analysis
Sponsors: Children's Oncology Group; Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified June 2013 - Conditions: Burkitt Lymphoma; Diffuse Large B-cell Lymphoma, c-MYC Positive
Interventions: Drug: rituximab; Drug: etoposide; Drug: cyclophosphamide; Drug: doxorubicin; Drug: vincristine; Drug: prednisone; Drug: filgrastim
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified July 2012 - Condition: Schizophrenia
Interventions: Other: Placebo; Other: L-methylfolate
Sponsors: Pamlab, Inc.; Pamlab, Inc.; Massachusetts General Hospital
Recruiting - verified May 2013 - Condition: Pain
Interventions: Other: Acupuncture, sham acupuncture or neither; Other: Acupuncture, sham acupuncture or neither
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; National Institutes of Health (NIH)
Recruiting - verified May 2013 - Condition: Pancreatic Cancer
Interventions: Biological: HyperAcute-Pancreas Immunotherapy; Drug: Gemcitabine; Radiation: 5FU Chemoradiation
Sponsors: NewLink Genetics Corporation; NewLink Genetics Corporation
Recruiting - verified June 2013 - Conditions: Non-small Cell Lung Cancer; EGFR Mutations
Intervention: Drug: BIBW 2992
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; University of Texas; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified June 2013 - Condition: Brain and Central Nervous System Tumors
Interventions: Drug: everolimus; Drug: temozolomide; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: Radiation Therapy Oncology Group; Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified June 2013 - Condition: HIV Infections
Intervention:
Sponsors: International Maternal Pediatric Adolescent AIDS Clinical Trials Group; International Maternal Pediatric Adolescent AIDS Clinical Trials Group; National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified June 2013 - Condition: Foot Ulcer, Diabetic
Interventions: Device: Integra® Dermal Regeneration Template; Other: Conventional Wound Therapy
Sponsors: Integra LifeSciences Corporation; Integra LifeSciences Corporation
Recruiting - verified June 2013 - Conditions: Influenza; (Influenza A and Subtypes Such as H3N2 and 2009 H1N1 or Influenza B)
Intervention:
Sponsors: University of Minnesota - Clinical and Translational Science Institute; University of Minnesota - Clinical and Translational Science Institute; National Institute of Allergy and Infectious Diseases (NIAID); National Institutes of Health (NIH)
Recruiting - verified June 2013 - Condition: Influenza
Intervention:
Sponsors: University of Minnesota - Clinical and Translational Science Institute; University of Minnesota - Clinical and Translational Science Institute; National Institute of Allergy and Infectious Diseases (NIAID); National Institutes of Health (NIH)
Recruiting - verified June 2013 - Conditions: Cancer; Cardiovascular Disease
Interventions: Dietary Supplement: vitamin D3; Drug: omega-3 fatty acids (fish oil); Dietary Supplement: Vitamin D3 placebo; Dietary Supplement: Fish oil placebo
Sponsors: Brigham and Women's Hospital; Brigham and Women's Hospital; National Cancer Institute (NCI); National Heart, Lung, and Blood Institute (NHLBI); Office of Dietary Supplements (ODS); National Institute of Neurological Disorders and Stroke (NINDS); National Center for Complementary and Alternative Medicine (NCCAM)
Recruiting - verified June 2013 - Condition: Infections
Intervention: Drug: Moxifloxacin (Avelox, BAY12-8039)
Sponsors: Bayer; Bayer
Recruiting - verified June 2013 - Conditions: Adverse Events; Usability Testing; Cognitive Testing
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified August 2012 - Conditions: Brain Cancer; Choroid Plexus Tumors
Interventions: Drug: Carboplatin; Drug: Cisplatin; Drug: Cyclophosphamide; Drug: Dactinomycin; Drug: Doxorubicin; Drug: Etoposide; Drug: Irinotecan; Drug: Leucovorin; Drug: Methotrexate; Drug: Temozolomide; Drug: Vincristine
Sponsors: Tufts Medical Center; Tufts Medical Center
Recruiting - verified June 2013 - Conditions: Cardiac Surgery; Erythrocyte Transfusion
Interventions: Biological: Red blood cell units stored <= 10 days; Biological: Red blood cell units stored >= 21 days
Sponsors: New England Research Institutes; New England Research Institutes; National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified May 2013 - Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: MM-121 (SAR256212) + erlotinib; Drug: Erlotinib
Sponsors: Merrimack Pharmaceuticals; Merrimack Pharmaceuticals; Sanofi
Recruiting - verified May 2013 - Conditions: Aplastic Anemia; Leukemia; Myelodysplastic Syndrome
Interventions: Drug: Busulfan, fludarabine, & cyclophosphamide with immunosuppression with ATG and cyclosporine.; Device: CliniMACS device
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Children's Hospital Boston; Children's Hospital Medical Center, Cincinnati; Children's Hospital and Health System Foundation, Wisconsin; Rockefeller University; Fred Hutchinson Cancer Research Center
Recruiting - verified June 2013 - Conditions: Ischemic Brain Injury; Stroke; Healthy Individual; Patent Foramen Ovale (PFO); Neurovascular Injury
Intervention:
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified May 2013 - Conditions: Childhood Hepatoblastoma; Stage I Childhood Liver Cancer; Stage II Childhood Liver Cancer; Stage III Childhood Liver Cancer; Stage IV Childhood Liver Cancer
Interventions: Procedure: therapeutic conventional surgery; Drug: cisplatin; Drug: fluorouracil; Drug: vincristine sulfate; Drug: doxorubicin hydrochloride; Drug: irinotecan hydrochloride; Procedure: liver transplantation; Other: laboratory biomarker analysis
Sponsors: Children's Oncology Group; Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified June 2013 - Condition: HIV Infections
Interventions: Drug: Raltegravir (RAL); Drug: Atazanavir (ATV); Drug: Ritonavir (RTV); Drug: Tenofovir (TDF); Drug: Etravirine (ETV); Drug: Darunavir (DRV); Drug: Maraviroc (MVC); Drug: Lopinavir/ritonavir (LPV/r)
Sponsors: International Maternal Pediatric Adolescent AIDS Clinical Trials Group; International Maternal Pediatric Adolescent AIDS Clinical Trials Group; National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified June 2013 - Condition: Lung Cancer
Interventions: Biological: panitumumab; Drug: carboplatin; Drug: paclitaxel
Sponsors: Radiation Therapy Oncology Group; Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified June 2013 - Condition: Acute Lymphoblastic Leukemia
Interventions: Drug: Prednisone; Drug: Vincristine; Drug: Doxorubicin; Drug: PEG-asparaginase; Drug: Cytarabine; Drug: Methotrexate; Drug: Imatinib; Drug: Clofarabine; Drug: 6 Mercaptopurine
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; Dana-Farber Cancer Institute; Beth Israel Deaconess Medical Center; Enzon Pharmaceuticals, Inc.; Genzyme
Recruiting - verified May 2013 - Condition: Cancer
Interventions: Drug: Lapatinib; Biological: Trastuzumab
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2013 - Condition: HIV Infections
Intervention: Drug: Highly active antiretroviral therapy (HAART)
Sponsors: International Maternal Pediatric Adolescent AIDS Clinical Trials Group; International Maternal Pediatric Adolescent AIDS Clinical Trials Group; National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified June 2013 - Condition: Alzheimer Disease
Intervention: Drug: ACC-001+ QS21
Sponsors: Pfizer; Pfizer; JANSSEN Alzheimer Immunotherapy Research & Development, LLC
Recruiting - verified June 2013 - Condition: Head and Neck Cancer
Interventions: Biological: cetuximab; Radiation: intensity-modulated radiation therapy
Sponsors: Radiation Therapy Oncology Group; Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified June 2013 - Condition: Related Hematopoietic Stem Cell Donors
Intervention:
Sponsors: Center for International Blood and Marrow Transplant Research; Center for International Blood and Marrow Transplant Research; National Institutes of Health (NIH); University of Utah; University of Pittsburgh
Recruiting - verified May 2013 - Condition: Exercise-related Amenorrhea
Interventions: Drug: Transdermal 17Beta-estradiol, progesterone; Drug: Ethinyl Estradiol + Desogestrel; Dietary Supplement: Sham Comparator
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified June 2013 - Condition: Carcinoma, Non-Small-Cell Lung
Intervention: Drug: PF-02341066
Sponsors: Pfizer; Pfizer
Recruiting - verified June 2013 - Conditions: Adult Rhabdomyosarcoma; Childhood Desmoplastic Small Round Cell Tumor; Chordoma; Desmoid Tumor; Metastatic Childhood Soft Tissue Sarcoma; Nonmetastatic Childhood Soft Tissue Sarcoma; Previously Treated Childhood Rhabdomyosarcoma; Previously Untreated Childhood Rhabdomyosarcoma; Recurrent Adult Soft Tissue Sarcoma; Recurrent Childhood Rhabdomyosarcoma; Recurrent Childhood Soft Tissue Sarcoma; Stage I Adult Soft Tissue Sarcoma; Stage II Adult Soft Tissue Sarcoma; Stage III Adult Soft Tissue Sarcoma; Stage IV Adult Soft Tissue Sarcoma
Interventions: Other: biologic sample preservation procedure; Other: laboratory biomarker analysis
Sponsors: Children's Oncology Group; Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified June 2013 - Condition: Glioblastoma Multiforme
Interventions: Device: NovoTTF-100A device; Drug: Temozolomide
Sponsors: NovoCure Ltd.; NovoCure Ltd.
Recruiting - verified May 2013 - Condition: Non-Small-Cell Lung Carcinoma
Interventions: Radiation: Photon Therapy; Radiation: Proton Therapy
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified June 2013 - Conditions: Parenteral Nutrition Associated Liver Disease; Short Bowel Syndrome; Gastrointestinal Disease
Intervention: Drug: Omegaven®
Sponsors: Children's Hospital Boston; Children's Hospital Boston
Recruiting - verified June 2013 - Condition: Breast Cancer
Interventions: Genetic: microarray analysis; Genetic: polymerase chain reaction; Genetic: protein expression analysis; Other: diagnostic laboratory biomarker analysis; Other: fluorescent antibody technique; Other: immunohistochemistry staining method; Other: immunologic technique
Sponsors: National Cancer Institute (NCI); Massachusetts General Hospital; National Cancer Institute (NCI)
Recruiting - verified April 2008 - Conditions: Graft Rejection; Kidney Transplant; Renal Allograft Recipients; Renal Transplant
Interventions: Drug: Tacrolimus; Drug: Sirolimus; Drug: Tacrolimus
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013 - Condition: Neuroblastoma
Interventions: Drug: Bevacizumab; Drug: cyclophosphamide; Drug: zoledronic acid
Sponsors: New Approaches to Neuroblastoma Therapy Consortium; New Approaches to Neuroblastoma Therapy Consortium; National Cancer Institute (NCI)
Recruiting - verified June 2013 - Conditions: Leukemia; Lymphoma
Interventions: Biological: filgrastim; Drug: asparaginase; Drug: bortezomib; Drug: cyclophosphamide; Drug: cytarabine; Drug: doxorubicin hydrochloride; Drug: etoposide phosphate; Drug: leucovorin calcium; Drug: methotrexate; Drug: pegaspargase; Drug: prednisone; Drug: therapeutic hydrocortisone; Drug: vincristine sulfate
Sponsors: Children's Oncology Group; Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified June 2013 - Condition: HIV Infection
Intervention: Drug: All licensed antiretroviral medications
Sponsors: University of Minnesota - Clinical and Translational Science Institute; University of Minnesota - Clinical and Translational Science Institute; National Institute of Allergy and Infectious Diseases (NIAID); Copenhagen HIV Programme (CHIP) -- Copenhagen, Denmark; Medical Research Council (MRC) Clinical Trials Unit -- London, United Kingdom; The Kirby Institute for Infection and Immunity in Society; The Institute for Clinical Research at the Veterans Affairs Medical Center -- Washington, D.C., USA; French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS); German Federal Ministry of Education and Research; NEAT - European AIDS Treatment Network; National Health and Medical Research Council, Australia; National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI); National Heart, Lung, and Blood Institute (NHLBI); National Institute of Mental Health (NIMH); National Institute of Neurological Disorders and Stroke (NINDS); National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); Abbott; Bristol-Myers Squibb; Gilead Sciences; GlaxoSmithKline; Merck; Tibotec Pharmaceutical Limited
Recruiting - verified June 2013 - Condition: Advanced Solid Malignancies
Intervention: Drug: REGN421(SAR153192)
Sponsors: Regeneron Pharmaceuticals; Regeneron Pharmaceuticals; Sanofi
Recruiting - verified May 2013 - Conditions: Acute Myeloid Leukemia; Acute Lymphoblastic Leukemia
Intervention: Drug: midostaurin
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2013 - Condition: Invasive Aspergillosis
Intervention: Drug: Voriconazole
Sponsors: Pfizer; Pfizer
Recruiting - verified June 2013 - Conditions: Brain Tumors; Spinal Cord Tumors
Interventions: Drug: Temozolomide; Drug: Lapatinib
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified June 2013 - Condition: Hepatocellular Cancer
Interventions: Drug: Sorafenib; Procedure: Radiofrequency Ablation
Sponsors: Dana-Farber Cancer Institute; Beth Israel Deaconess Medical Center; Dana-Farber Cancer Institute; Brigham and Women's Hospital; Bayer; Onyx Therapeutics, Inc.; National Cancer Institute (NCI)
Recruiting - verified May 2013 - Condition: Colorectal Cancer
Intervention: Other: Colonoscopic examination
Sponsors: University Health Network, Toronto; University Health Network, Toronto; Princess Margaret Hospital, Canada
Recruiting - verified June 2013 - Condition: Healthy
Intervention: Drug: Filgrastim
Sponsors: Center for International Blood and Marrow Transplant Research; Center for International Blood and Marrow Transplant Research; National Marrow Donor Program
Recruiting - verified May 2013 - Conditions: Cataract; Macular Degeneration
Interventions: Drug: selenium; Drug: vitamin E; Drug: vitamin E placebo; Drug: selenium placebo
Sponsors: Southwest Oncology Group; Southwest Oncology Group; National Cancer Institute (NCI); National Eye Institute (NEI)
Recruiting - verified June 2013 - Conditions: Chemotherapeutic Agent Toxicity; Cognitive/Functional Effects; Neurotoxicity; Psychosocial Effects of Cancer and Its Treatment; Radiation Toxicity; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Other: questionnaire administration; Procedure: cognitive assessment; Procedure: psychosocial assessment and care; Procedure: quality-of-life assessment
Sponsors: Children's Oncology Group; Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified June 2013 - Condition: Osteosarcoma
Interventions: Drug: Saracatinib; Drug: Placebo
Sponsors: Sarcoma Alliance for Research through Collaboration; Sarcoma Alliance for Research through Collaboration; AstraZeneca
Recruiting - verified May 2013 - Conditions: Accelerated Phase Chronic Myelogenous Leukemia; Acute Myeloid Leukemia/Transient Myeloproliferative Disorder; Acute Undifferentiated Leukemia; Angioimmunoblastic T-cell Lymphoma; Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative; Blastic Phase Chronic Myelogenous Leukemia; Childhood Acute Lymphoblastic Leukemia in Remission; Childhood Acute Myeloid Leukemia in Remission; Childhood Burkitt Lymphoma; Childhood Chronic Myelogenous Leukemia; Childhood Diffuse Large Cell Lymphoma; Childhood Grade III Lymphomatoid Granulomatosis; Childhood Immunoblastic Large Cell Lymphoma; Childhood Myelodysplastic Syndromes; Childhood Nasal Type Extranodal NK/T-cell Lymphoma; Chronic Eosinophilic Leukemia; Chronic Myelomonocytic Leukemia; Chronic Neutrophilic Leukemia; Chronic Phase Chronic Myelogenous Leukemia; Cutaneous B-cell Non-Hodgkin Lymphoma; Essential Thrombocythemia; Extramedullary Plasmacytoma; Intraocular Lymphoma; Isolated Plasmacytoma of Bone; Juvenile Myelomonocytic Leukemia; Long-term Effects Secondary to Cancer Therapy in Children; Mast Cell Leukemia; Meningeal Chronic Myelogenous Leukemia; Monoclonal Gammopathy of Undetermined Significance; Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Polycythemia Vera; Post-transplant Lymphoproliferative Disorder; Primary Central Nervous System Hodgkin Lymphoma; Primary Central Nervous System Non-Hodgkin Lymphoma; Primary Myelofibrosis; Primary Systemic Amyloidosis; Progressive Hairy Cell Leukemia, Initial Treatment; Prolymphocytic Leukemia; Secondary Acute Myeloid Leukemia; Secondary Myelodysplastic Syndromes; Stage 0 Chronic Lymphocytic Leukemia; Stage I Childhood Anaplastic Large Cell Lymphoma; Stage I Childhood Hodgkin Lymphoma; Stage I Childhood Large Cell Lymphoma; Stage I Childhood Lymphoblastic Lymphoma; Stage I Childhood Small Noncleaved Cell Lymphoma; Stage I Chronic Lymphocytic Leukemia; Stage I Cutaneous T-cell Non-Hodgkin Lymphoma; Stage I Multiple Myeloma; Stage I Mycosis Fungoides/Sezary Syndrome; Stage II Childhood Anaplastic Large Cell Lymphoma; Stage II Childhood Hodgkin Lymphoma; Stage II Childhood Large Cell Lymphoma; Stage II Childhood Lymphoblastic Lymphoma; Stage II Childhood Small Noncleaved Cell Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage II Cutaneous T-cell Non-Hodgkin Lymphoma; Stage II Multiple Myeloma; Stage II Mycosis Fungoides/Sezary Syndrome; Stage III Childhood Anaplastic Large Cell Lymphoma; Stage III Childhood Hodgkin Lymphoma; Stage III Childhood Large Cell Lymphoma; Stage III Childhood Lymphoblastic Lymphoma; Stage III Childhood Small Noncleaved Cell Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Cutaneous T-cell Non-Hodgkin Lymphoma; Stage III Multiple Myeloma; Stage III Mycosis Fungoides/Sezary Syndrome; Stage IV Childhood Anaplastic Large Cell Lymphoma; Stage IV Childhood Hodgkin Lymphoma; Stage IV Childhood Large Cell Lymphoma; Stage IV Childhood Lymphoblastic Lymphoma; Stage IV Childhood Small Noncleaved Cell Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma; Stage IV Mycosis Fungoides/Sezary Syndrome; T-cell Large Granular Lymphocyte Leukemia; Unspecified Childhood Solid Tumor, Protocol Specific; Untreated Childhood Acute Lymphoblastic Leukemia; Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies; Untreated Hairy Cell Leukemia; Waldenström Macroglobulinemia
Interventions: Other: survey administration; Procedure: assessment of therapy complications; Procedure: long-term screening; Procedure: study of high risk factors
Sponsors: Children's Oncology Group; Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified June 2013 - Condition: Human Immunodeficiency Virus
Interventions: Drug: Maraviroc along with an optimized background antiretroviral drug regimen; Drug: Optimized background antiretroviral drug regimen without maraviroc
Sponsors: ViiV Healthcare; ViiV Healthcare; Pfizer
Recruiting - verified May 2013 - Condition: Chronic Pain
Intervention:
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital
Recruiting - verified May 2013 - Condition: Lung Cancer
Interventions: Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy; Drug: cisplatin; Drug: etoposide
Sponsors: Alliance for Clinical Oncology Trials; Cancer and Leukemia Group B; National Cancer Institute (NCI); Radiation Therapy Oncology Group; Eastern Cooperative Oncology Group; North Central Cancer Treatment Group; Southwestern Oncology Group (SWOG)
Recruiting - verified June 2013 - Conditions: Aspergillosis; Invasive Fungal Infections
Intervention: Drug: isavuconazole
Sponsors: Astellas Pharma Inc; Astellas Pharma Inc; Basilea Pharmaceutica
Recruiting - verified June 2013 - Conditions: Transthyretin Mutations; Transthyretin Amyloidosis
Intervention: Other: None. Observational Study.
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013 - Conditions: Crohn's Disease; Ulcerative Colitis; Indeterminate Colitis; Inflammatory Bowel Diseases
Interventions: Biological: Anti TNF therapy including infliximab; Drug: No Biologics
Sponsors: Janssen Biotech, Inc.; Janssen Biotech, Inc.
Recruiting - verified June 2013 - Conditions: Systemic Anaplastic Large-Cell Lymphoma; Neoplasms; Anaplastic Lymphoma Kinase, Human; NSCLC
Interventions: Drug: PF-02341066; Drug: Rifampin; Drug: Ketoconazole
Sponsors: Pfizer; Pfizer
Recruiting - verified June 2013 - Condition: CSF Flow Through the Shunt of a Hydrocephalus Patient
Intervention: Device: ShuntCheck
Sponsors: NeuroDx Development; NeuroDx Development; Children's Hospital Boston
Recruiting - verified June 2013 - Condition: Prostate Cancer
Interventions: Drug: bicalutamide; Drug: flutamide; Radiation: radiation therapy
Sponsors: Radiation Therapy Oncology Group; Radiation Therapy Oncology Group; National Cancer Institute (NCI); Cancer and Leukemia Group B
Recruiting - verified June 2013 - Condition: Graft-vs-Host Disease
Intervention: Drug: Sirolimus, MMF
Sponsors: Dana-Farber Cancer Institute; Dana-Farber Cancer Institute; Wyeth is now a wholly owned subsidiary of Pfizer; PDL BioPharma, Inc.
Recruiting - verified June 2013 - Condition: Influenza
Interventions: Drug: oseltamivir; Drug: oseltamivir; Other: Alternative Control
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified June 2013 - Conditions: Acute Liver Failure; Fulminant Hepatic Failure; Acute Liver Injury
Intervention:
Sponsors: University of Texas Southwestern Medical Center; William Lee; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified June 2013 - Conditions: Psoriasis; Arthritis, Psoriatic
Interventions: Biological: ustekinumab; Biological: Biological therapies other than infliximab and ustekinumab; Drug: conventional systemic agents; Biological: infliximab
Sponsors: Centocor Ortho Biotech Services, L.L.C.; Centocor Ortho Biotech Services, L.L.C.
Recruiting - verified June 2013 - Condition: Kidney Transplant
Interventions: Drug: ramipril; Drug: ramipril
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013 - Conditions: Aphasia; Nonfluent Aphasia; Stroke
Intervention:
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs; Boston University
Recruiting - verified May 2013 - Phase 1 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple MyelomaCondition: Multiple Myeloma
Intervention: Drug: NPI-0052
Sponsors: Triphase Research and Development I Corporation; Triphase Research and Development I Corporation
Recruiting - verified May 2013 - Condition: HIV Infections
Interventions: Drug: Emtricitabine/tenofovir disoproxil fumarate; Drug: Placebo
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID); Bill and Melinda Gates Foundation
Recruiting - verified May 2013 - Conditions: Untreated Childhood Medulloblastoma; Untreated Childhood Pineoblastoma; Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor
Interventions: Drug: carboplatin; Drug: cyclophosphamide; Biological: filgrastim; Drug: cisplatin; Drug: isotretinoin; Drug: vincristine sulfate; Radiation: radiation therapy; Other: laboratory biomarker analysis
Sponsors: Children's Oncology Group; Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified June 2013 - Conditions: Retinitis Pigmentosa; Inherited Ophthalmic Diseases
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Eye Institute (NEI)
Recruiting - verified May 2013 - Condition: Hereditary Oral Clefts
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Human Genome Research Institute (NHGRI)
Recruiting - verified May 2013 - Conditions: Untreated Childhood Medulloblastoma; Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor
Interventions: Drug: etoposide; Drug: cyclophosphamide; Drug: cisplatin; Biological: filgrastim; Drug: carboplatin; Drug: thiotepa; Drug: methotrexate; Drug: leucovorin calcium; Drug: vincristine sulfate; Procedure: autologous hematopoietic stem cell transplantation; Other: laboratory biomarker analysis; Procedure: quality-of-life assessment
Sponsors: Children's Oncology Group; Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified June 2013 - Condition: Kidney Cancer
Interventions: Biological: dactinomycin; Drug: carboplatin; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: irinotecan hydrochloride; Drug: vincristine sulfate; Procedure: therapeutic conventional surgery; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: Children's Oncology Group; Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified June 2013 - Condition: Anemia, Aplastic
Interventions: Drug: Cyclophosphamide; Drug: Cyclophosphamide; Drug: Cyclophosphamide; Drug: Cyclophosphamide
Sponsors: Medical College of Wisconsin; Medical College of Wisconsin; National Heart, Lung, and Blood Institute (NHLBI); Blood and Marrow Transplant Clinical Trials Network; National Cancer Institute (NCI)
Recruiting - verified June 2013 - Condition: Hypereosinophilic Syndrome
Intervention: Drug: mepolizumab
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2013 - Condition: Sarcoma
Intervention: Drug: Trabectedin
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified May 2013 - Condition: HIV Infection
Intervention: Drug: Efavirenz
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Available - verified May 2013 - Conditions: Non-Hodgkin's Lymphoma; Hodgkin's Disease; Leukemia, Lymphocytic, Chronic; Lymphoproliferative Disorders
Intervention:
Sponsors: Dana-Farber Cancer Institute; Dana-Farber Cancer Institute
Recruiting - verified May 2013 - Condition: Diabetes Mellitus, Type 1
Intervention:
Sponsors: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National Institute of Allergy and Infectious Diseases (NIAID); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Center for Research Resources (NCRR); Juvenile Diabetes Research Foundation; American Diabetes Association
Recruiting - verified May 2013 - Conditions: Brain Tumor; Central Nervous System Tumor
Interventions: Drug: cisplatin; Drug: cyclophosphamide; Drug: lomustine; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: Children's Oncology Group; Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified June 2013 - Conditions: Cancer Survivor; Cardiovascular Complications; Hematopoietic/Lymphoid Cancer; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Other: questionnaire administration; Other: laboratory biomarker analysis
Sponsors: Children's Oncology Group; Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified June 2013 - Condition: HIV Infections
Intervention: Drug: Tipranavir
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Available - verified June 2013 - Conditions: Glioblastoma Multiforme; Glioblastoma; GBM; Grade IV Astrocytoma; Glioma; Brain Cancer; Brain Tumor
Intervention: Drug: Dendritic cell immunotherapy
Sponsors: Northwest Biotherapeutics; Northwest Biotherapeutics
Recruiting - verified May 2013 - Condition: HIV Infections
Interventions: Drug: Current ARV medications; Drug: Current TB medications; Drug: Current hormonal contraceptive medications
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified May 2013 - Conditions: HIV Infections; Pregnancy Complications, Infectious
Intervention: Behavioral: Adherence assessment
Sponsors: International Maternal Pediatric Adolescent AIDS Clinical Trials Group; International Maternal Pediatric Adolescent AIDS Clinical Trials Group; National Institute of Allergy and Infectious Diseases (NIAID); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified June 2013
 |
Find Paid Research Studies in Boston, Massachusetts |
Clinical Trial Locations 